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This dissertation contains two major projects. The first project focused on the design 
and synthesis of small molecule inhibitors of the methyl erythritol phosphate (MEP) pathway. 
Known as a non-mevalonate isoprenoid biosynthetic pathway, plants and apicomplexan 
protozoa such as malaria parasites use this to produce isoprenoids (terpenoids). Additionally, 
most bacteria, including pathogens such as Mycobacterium tuberculosis, synthesize IPP and 
DMAPP via the non-mevalonate pathway.1 Among the seven enzymes involved in this 
pathway, a highly conserved enzyme is 2C-methyl-D-erythritol 2,4-cyclodiphosphate synthase 
(IspF). Fragment screening hits on Burkholderia pseudomallei IspF (BpIspF) afforded the basis 
for our chemistry leads, allowing the design of new potential IspF inhibitors.  Three major 
series of compounds were synthesized by efficient methods that allowed for exploration of the 
IspF binding site and modification of the physiochemical properties. Fragment based screening 
of the BpIspF enzymes performed by Dr. Darren Begley provided additional hits that 
significantly expanded the diversity of the chemical cores and additional leads for the design of 
novel inhibitors.  Guided by the biophysical methods of surface plasma resonance (SPR), we 
  
are able to obtain the binding potencies of compounds and generate structure activity 
relationships (SAR) for the chemical series.  Computational studies using the docking module 
in the program SYBYL-X assisted in the exploration and visualization of potential binding 
motifs and allowed the rational design of new potential BpIspF inhibitors. This work forms the 
foundation for further medicinal chemistry efforts on the optimization of MEP pathway 
inhibitors and the modification of existing IspF enzymatic assays.  
The second project involved the development of a concise synthesis of PDE4D 
allosteric modulators and applications toward the synthesis of new PDE4D inhibitors. 
Phosphodiesterases (PDEs) are responsible for the hydrolysis of cAMP and cGMP and are 
highly conserved in their catalytic domains of all super family members.
2,3
 Phosphodiesterase 4 
(PDE4) is one of enzymes present in inflammatory and immune cells, which can be targeted as 
potential therapeutic agent for central nervous system (CNS) and respiratory disease.
4,5
 As one 
of the four protein isoforms, PDE4D has been intensely investigated and a series of partial 
PDE4D inhibitors overcame the severe nausea side effects that were plaguing clinical PDE4 
inhibitors.
2
 To improve the reported six-step synthesis of the PDE4D inhibitor D159687 that 
had an 8% overall yield, a concise two-step synthesis was developed using sequential Suzuki 
couplings that significantly increased the yield to 40% and provided a convergent synthesis that 
allows for rapid analog synthesis. The convergent synthetic route developed for the PDE4D 
inhibitors allowed for the synthesis of atropisomeric compounds.  A method to separate the 
atropisomeric PDE4D inhibitors was developed using chiral HPLC. The atropisomeric PDE4D 
inhibitors will open an opportunity to study the binding modes and biological activity of these 
inhibitors.
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Methyl erythritol phosphate (MEP) biosynthetic pathway 
 
 Isoprenoids, which are derived from isopentenyl diphosphate (IPP) and dimethylallyl 
diphosphate (DMAPP), comprise diverse metabolites responsible for cellular functions.
6
 Two 
distinct pathways are responsible for the production of isoprenoids. Mevalonate-dependent 
biosynthetic (MAD) pathway present in plants, archaea, fungi and mammals,
7
 involves the 
enzyme HMG-CoA reductase that has various biological effects such as protein prenylation, cell 
membrane maintenance and steroid biosynthesis. Currently, statin drugs target the HMG-CoA 












Figure 2 MEP biosynthetic pathway 
 Compared to the MAD pathway, the MEP (methyl erythritol phosphate) pathway (Figure 
2) is an alternative metabolic pathway for the synthesis of IPP and DMAPP, which is widely 
present in higher plants, algae, bacteria, and malarial parasites.
7
 It was first discovered by Michel 
Rohmer in 1990’s by a isotope labeling experiments.9 To be more specific, MEP is essential in 
Plasmodium falciparum, Mycobacterium tuberculosis, Toxoplasma gondii, Burkholderia 
pseudomallei, Escherichia coli, and other infectious diseases causing organisms.
6,10
 Enzymes 





herbicides with minimal human host toxicity. The anti-infective compound fosmidomycin was 
discovered to inhibit the IspC enzyme in the MEP pathway and is currently in phase II clinical 
trials in combination of clindamycin to treat malaria.
6
 However, enzyme selectivity, 
bioavailability and increasing drug-resistance pose hurdles in developing fosmidomycin as an 
effective treatment for malaria. The driving force for my research is to design, synthesize and 
evaluate novel inhibitors with improved activity against enzymes in the MEP pathway, which 
might lead to new anti-infective agents in the future.  
 Among the seven enzymes in the pathway, my research focused on 2-C-methyl-D-
erythriol 4-phosphate cytidyltransferase (IspD), 4-diphosphocytidyl-2-C-methyl-D-erythritol 
kinase (IspE), and 2-C-methyl-D-erythritol 2,4-cyclodiphosphate synthase (IspF) since we had a 
number of fragment hits and more than 100 protein crystal structures that were obtained by the 
Seattle Structural Genomic Center for Infectious Disease (SSGCID) that were deposited in the 
Protein Data Bank (PDB). In the MEP pathway, IspD catalyzes the coupling of 2-C-methyl-D-
erythritol 4-phosphate (MEP) with CTP to afford 4-diphosphocytidyl-2C-methyl-d-erythritol 
(DCP-ME). The CDP-ME is then converted to 4-diphosphocytidyl-2-C-methyl-D-erythritol 2-
phosphate (CDP-MEP) by IspE. Finally, CDP-MEP is cyclized via IspF catalysis to afford 2-C-
methyl-D-erythritol 2,4-cyclopyrophosphate (MEcPP).   
 
Fragment-based screening of targets involved in MEP pathway 
 
 In medicinal chemistry, various screening strategies are applied to discover new chemical 





methods are known to be an effective approach for early stage drug development. The fragments 
are generally molecules with molecular weights lower than 300 Da.
11
 Fragment screening used 
and synthetic approaches which follow three key steps. The steps include fragment library 
design, fragment screening and fragment elaboration cycle.
11
 The first example that successfully 
used a fragment screening approach that resulted in a FDA approved medicine was Zelboraf.
12
 In 
our research, the fragment based screening method offers a rational and validated approach to 
proceed from a small fragment hit, usually a molecule with millimolar activity, to the discovery 
of potential lead molecules with high ligand efficiency and micromolar affinity for the enzyme. 
 To start the screening process, our collaborators at Emerald Biostructures obtained X-ray 
crystallographic information for enzymes within the MEP pathway and ligand-bound complex 
structures. All the ligands can be considered as fragment hits and offered  rational structure-
guided drug design.
13
 Although a variety of  fragment screening methods such as ligand-based 
NMR, surface plasma resonance (SPR), and calorimetry can be used to generate fragment hits, 
problems still exist in these methods including inadequate binding specificity and deficiency of 
structural information, respectively.
13
 By contrast, fragment screening by X-ray crystallography 
provides direct target-hit details and provides structural information for the binding site. Typical 
fragment molecules are less than 300 Da which show great per-atom binding efficiency despite 
the fact of weak overall affinity.
14,15
 As an early stage of compound screening, our goal was to 
quickly determine the potential hits and generate a library for further hit to lead optimization. 
Additionally, fragment screening by X-ray crystallography of small molecules can also can be 
used to locate the “hot spots” inside the protein with energy optimization.  This technique 
remains a challenge for larger molecules selected by high-throughput screening (HTS) due to 
their extra bulk and steric effects.
13





from Emerald Biostructures  performed the screening of enzymes from MEP pathway beginning 
with fragment library screening  followed by target selection (restricted by Rule of 3
11
 criteria, 
including MW < 300, hydrogen bond donor and receptor < 3, partition coefficient (LogP) < 3), 
crystal growth and crystal soaking.
13
 In the end, structural data was collected and binding site 






Figure 3 Fragment hits for BpIspF 
 Sequence analysis reveals over 30% identity for IspF proteins across prokaryotic and 
eukaryotic species with high conservation within the substrates binding site.
13,16
 B. pseudomallei 
IspF (BpIspF) was chosen for the fragment screening due to its ability for crystal formation with 
ligands.
13





pockets. Cytidine, CMP, CDP and CTP can bind to the cytidine pocket and mimic the native 
substrate, 4-diphospho-cytidyl-2-C-methyl-D-erythritol 2-phosphate.
13,17
 Several heteroatom 
containing aromatic molecules show interactions with the zinc atom in the other pocket based on 
the screening with the Fragment of Life
TM 




 After the fragment hits was successfully generated, three methods need to be consider in 
the process of  fragment elaboration cycle: fragment merging, fragment linking and fragment 
growing.
11
 In my research, I focus on the fragment linking and growing methods to rationally 
design lead molecules. With two pockets successfully identified, we began to analyze the 
possibility of linking the fragment hits that bound to the cytidine and zinc pockets. As described 
previously in this dissertation, the theory behind fragment based screening is to build a target 
ligand from separate hits. First, crystal structures showed CMP, CDP and CTP bind to the 
cytidine pocket with the phosphate groups binding with the zinc ion. This technique afforded a 
target lead molecule with cytosine moiety and ribose ring as a connection to various zinc binding 
groups from the fragment hits, which may conformationally mimic the binding pattern of CMP, 
CDP and CTP. Secondly, installation of zinc binding groups on the ribose ring of cytidine is a 
facile approach from a synthetic chemistry perspective that allows the use of a common 
intermediate. Further discussion for the synthesis of fusion compounds, their affinities against 
BpIspF and details for the analysis of binding site will be discussed later in this dissertation. 
 In addition to IspF, Dr. Darren Begley (at Emerald Biostructures) was also able to 
investigate IspD and IspE by applying saturated transfer difference nuclear magnetic resonance 
(STD NMR).
18







 It first applies a selective saturated pulse and then detects the signal differences 
between the saturated ligand-protein form and the free protein form. Subtraction of these two 
spectra will result in a signal which only shows the molecules that bind to the enzyme resulting 
in fragment hits.
19
 Darren Begley was able to generate additional fragment hits by this method in 
a short period of time with a minimum amount of protein. Interestingly, some chemical series 
have more than one fragment hit which indicates their potential to inhibit enzymes from the MEP 
pathway, even though the enzyme selectivity needs to be considered in the future for these 
enzyme binding assays. Figure 4 shows the result of different chemical series as fragment hits for 















 We applied fragment screening as a method to initiate the design of IspF inhibitors. Two 
distinct pockets were shown to be present by X-ray crystallography. Cytosine, cytidine and 
cytidine phosphate derivatives are observed crystallographically in the cytidine binding pocket 
while a range of chemical entities with differing orientations bind in the zinc pocket. The 
observation was made that in the zinc pocket, each chemical moiety coordinates to the metal 
through the nitrogen from the aromatic system.
10,16
 The fusion molecules, which fuse the 
cytidine fragment to various zinc binding fragments, were designed as the initial targets based 
upon synthetic accessibility and feasibility to test our hypothesis of fragment linking inhibitor 
design.  Among five target molecules, the cytidine moiety is retained while other heteroaromatic 
fragments that are capable of binding to the zinc ion are attached through an amide bond.  
 
Synthesis of IspF inhibitors 
 
 Synthesis of fusion compounds began with intermediate 1, which was synthesized 
according to literature procedure in six steps from commercially available (+)-cytidine.
21
 Target 
fusion compounds were obtained by amide formation followed by deprotection. Two different 
amide coupling procedures were utilized. First, 3 was synthesized from 1 by coupling with the 
commercially available acid chloride 2 (Scheme 1). Compounds 4-7 were synthesized from 1 





deprotection of acetonide and DMT with trifluoroacetic acid in acetonitrile/water (Scheme 















Surface plasmon resonance (SPR) analysis 
 
 An SPR assay (performed by Sriram Jakkaraju) was used to investigate the equilibrium 
dissociation constant of compounds 4-7 for BpIspF.
22
 First, BpIspF was immobilized using 
random amine by EDC (Ethyl-N′-(3-dimethylaminopropyl)carbodiimide hydrochloride)\NHS 
(N-hydroxysuccinimide coupling to a carboxylmethyl dextran SPR slide. Second, concentration 
series for each compound from 2 mM to 1.7 μM (5% DMSO) were generated by serial dilution 
and injected over the IspF surface. Additionally, buffer-only injections were introduced between 
every compound injection. Finally, Scrubber (BioLogic Software) was used to process the data 
with double referencing (subtraction of buffer-only injection and reference flow cell). The 
binding responses which were recorded as a function of time allow equilibrium to be established. 
KD values were obtained by fitting the data to a 1:1 Langmuir binding model. 
 Cytidine diphosphate (CDP) was chosen as a reference and resulted in an observed KD of 
75 μM, which was close to the KD determined by Ramsden for IspF from E. coli.
22
 Fusion 
compounds had an observed KD from 70 to 200 μM without the diphosphate group which was 
recognized as essential interactions for CDP to bind to the zinc in the active site. Besides all five 
fusion molecules, two fragment hits (FOL717 and FOL955) were also tested to compare their 
affinity with fusion compounds. Additionally, docking scores were generated by Sybyl software 
and served as a computational evaluation based on conformational energy minimization, 
hydrogen bindings and other potential interactions of fusion compounds in the active site of 
BpIspF. Larger docking scores indicated compounds with better calculated binding interactions. 
Interestingly, the calculated scores showed a general correlation with the observed affinity values 






Table 1 SPR assay (performed by Sriram Jakkaraju) and docking results (performed by Joy Blain) 




CDP 75 N.A. 
3 180 8.11 
4 148 8.34 
5 70 8.91 
6 200 7.13 
7 90 8.45 
FOL717 135 N.A. 
FOL955 >500 N.A. 
 
 
Structural analysis by computational methods 
 
 To further analyze the interactions of the fusion molecules, co-crystal structures were 
obtained for two out of five lead compounds (3 and 5) with BpIspF (Dr. Darren Begley) 
Alignment of crystal structures confirmed our design strategy. Compound 3 was first 







Figure 5 Crystal structures of BpIspF which contains compound 3 (in green) and FOL8395 (in cyan) 
overlaid (PDB: 3KE1 and 3JVH). 
 Generally, the cytosine moiety will fit into the cytidine pocket through the hydrogen 
bonding by the amino and carbonyl group (labeled in Figure 4 as 1 and 2). On the other side of 
the ligand, hetero atom (N atom in all the cases) binds to the zinc (showed as dark sphere), which 
is also coordinated to two histidine residues (His44, His10 and Asp10). The hydroxyl groups of 
the ribose ring have hydrogen bonding to aspartic acid (Asp58). The cytosine moiety of 
compound 3 interacts with Ala102, Pro105, Ala108 and the pyridyl nitrogen binds directly to the 
zinc. Next, we investigated the crystal structure of compound 5 aligned with FOL717 in the 
active site (Figure 6). In this case FOL717 interacts with the zinc by the nitrogen on the 
imidazothiazole core directly while the nitrogen on the imidazothiazole moiety of compound 5 
binds to the zinc through a water molecule. A similar KD value is observed for 5 as compared to 







hypotheses can be made: (1) Other heteroatom containing moiety can still interact with the zinc 
rather than the phosphate group in CDP (2) The increase of binding affinity indicates that 
bicyclic group of compound 5 creates a potential hydrophobic interaction with the pocket made 
by Ile59, Phe63 and Leu78, which is above zinc in the BpIspF active site.  
 
Figure 6 Crystal structures of compound 5 (in green) and FOL717 (in cyan) in BpIspF overlaid (PDB: 
3Q8H and 3IKF).  
 To further study the hydrophobic interaction, molecular docking was performed using 
SYBYL X-2.0. We first prepared the entry of crystal structure of compound 5 (PDB: 3Q8H) and 
then use Surflex-Dock Geom to introduce free ligand of compound 7. All water molecules were 
removed and the optimized binding was proposed by minimizing the binding energy 
computationally. As the predicted and experimental binding modes showed, main differences are 
found in the ribose ring and the zinc binding site although cytidine binding pose remains 





study, we hypothesized that this hydrophobic interaction is essential for design of the future lead 
molecules (Figure 7). 
 
Figure 7 Crystal structures of compound 5 (in cyan, PDB: 3Q8H) and docking pose of compound 7 (in 
green) overlaid.  
 
Anti-bacterial and anti-malarial assay 
 
 In addition to the SPR assay, anti-bacterial test against Burkholderia thailandensis and 
anti-malarial test against Plasmodium falciparum D6, C235, W2 strains (drug resistant strains) 
were performed according to reported method.
23-25
 B. thailandensis was chosen for the in vivo 
anti-bacterial assay of fusion compounds because it does not require biosafety level 3 (BSL-3) 
facility.
23,26
 and its IspF enzyme displays 98% sequence identity at the nucleotide level with B. 
pseudomallei. We collaborated with Dr. Peggy Cotter at the University of North Carolina at 





highest concentration (1mM). Additionally, through collaboration with Dr. Richard Sciotti at the 
Walter Reed Army Institute of Research (WRAIR) the fusion compounds were assayed against 
Plasmodium falciparum D6 (chloroquine sensitive but mefloquine resistant), C235 (multiple 
drugs resistant) and W2 (chloroquine resistant but mefloquine sensitive).
24
 Plasmodium 
falciparum is the most dangerous malaria parasite with highest rate of mortality and increasing 
drug resistance. By targeting these strains we could evaluate the effectiveness of fusion 
compounds and compare their IC50 values to the known anti-malarial agent such as mefloquine 
and chloroquine.  The results showed greater than 40 μM across all three strains for fusion 
compounds which are considered as weak affinity compared to sub-micromolar affinity of 
Mefloquine and Chloroquine.
27
 The anti-bacterial and anti-malarial data may result from the 
negative LogP of the compounds which forbids them to penetrate the lipophilic cell wall and 





 To summarize, we successfully generated five fusion compounds which were synthesized 
based on the fragment hits. In order to test the hypothesis that a fragment linking approach would 
lead to more potent IspF ligands, fusion molecules were designed.  The fusion molecules linked 
a cytidine and five different zinc binding groups through an amide bond.  The BpIspF binding 
affinity data was collected using an SPR assay. Compared to cytidine,  which was only observed 
with weak binding affinity (Dr. Darren Begley), the fusion compounds exhibited improvement 





fragment hit such as CDP, which showed 100 μM against EcIspF and 75 μM against BpIspF. All 
these results confirmed our initial hypothesis for the linking of fragment hits. We were able to 
perform the “hit to lead” method and build a chemical series with micromolar affinity for 
BpIspF. Moreover, docking by SYBYL offers additional structural insight on the binding mode 
using available protein crystal structures. We discovered a hydrophobic pocket that allows 
additional interactions for compounds that bind to BpIspF and provides potential interaction for 
optimizing the binding affinity. This hydrophobic pocket will be targeted in future work.  





 All commercially available reagents were used without further purification. Column 
chromatography was performed on silica gel (230−400 mesh) using a Biotage Isolera One. 
Reverse phase chromatography was performed utilized a Biotage SNAP Cartridge (KP-C18-HS) 
on a Biotage Isolera One. The gradient consisted of two solvents:  solventA---water with 
0.1%TFA and solventB---acetonitrile (100%A to 100%B over 10 min). 
1
H NMR and 
13
C NMR 
spectra were recorded on an Avance III 300 MHz NMR (Bruker Biospin from Billenca, using 
BBFO probe, 5 mm). Analytical HPLC were recorded on an Agilent 1100 HPLC system using a 
C-18 column (Waters Nova-Pak 3.9 x 150 mm) with the following gradient: 90:10 water (0.1% 
TFA) to acetonitrile to 10:90 water (0.1% TFA) to acetonitrile over 40 minutes. Samples were 






Surface plasmon resonance 
 SPR binding experiments were performed on a Reichert SR7000DC (with a SR7500DC 
upgrade) using a high density 500,000 Da carboxymethyl dextran SR7000 gold sensor slide. IspF 
was coupled to the sensor slide using amine coupling chemistry. Initially, the surface was 
activated by injecting a mixture of 75 mg/ml EDC (N-Ethyl-N′-(3-
dimethylaminopropyl)carbodiimide hydrochloride) and 11.5 mg/ml NHS (N-
hydroxysuccinimide) for 7 min using a 50 μl/min flow rate.  IspF, diluted in 10 mM 5.0 pH 
sodium acetate buffer at a final concentration of 120 μg/ml, was injected over the surface for 10 
min at 30 μl/min. Excess succinamide ester groups were quenched with an injection of 1M 
ethanolamine for 6 min with a 50 μl/min flow rate. A total of 4000-7500 μRIU (Refractive index 
units) of IspF were coated on the slide. Binding experiments were conducted at 20°C in 50 mM 
sodium phosphate pH 7.4/150 mM NaCl/4.76% DMSO at 50 μl/ min. Initially, compounds were 
dissolved in DMSO at 20 mM and were diluted (20-fold) into 50 mM sodium phosphate pH 
7.4/150 mM NaCl, to produce a 1 mM compound sample with 4.76% DMSO, thereby 
minimizing buffer mismatch. A concentration series of compound from 1 mM to 0.8 μM (diluted 
using running buffer) was generated and injected over the IspF surface. Blank (Buffer-only) 
injections were included between each compound injection, allowing for double subtraction 
(reference cell and buffer) during data processing. Data processing and analysis was performed 
using Scrubber (BioLogic Software). 
 
4-amino-1-((2R,3R,4S,5R)-5-(aminomethyl)-3,4-dihydroxytetrahydrofuran-2-yl)pyrimidin-
2(1H)-one (1): 1 was synthesized by the reported method
21





chromatography (Et3N/MeOH/EtOAc = 1/10/89) yielding 1 (1.90 g, 77%). 
1
H NMR (CDCl3, 
300 MHz): δ1.34 (s, 3H); 1.55 (s, 3H); 2.36 (s, 3H); 4.01 (dd, J = 14, 5 Hz, 1H), 4.17 (dd, J = 14, 
8.5 Hz, 1H); 4.52-4.55 (m, J = 5.7, 1H); 4.97 (dd, J = 6.5, 4 Hz, 1H); 5.21 (d, J = 6 Hz, 1H); 5.63 
(s, 1H); 7.50 (d, J = 7.5 Hz, 1H); 6.82-6.89 (m, 4H); 7.06 (d, J =9 Hz, 1H); 7.18-7.24 (m, 4H); 
7.32-7.37 (m, 5H). 
 
N-(((2R,3S,4R,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-3,4-dihydroxytetrahydrofuran-2-
yl)methyl)isonicotinamide (3): To a solution of 1 (0.33 g, 0.564 mmol) and Et3N (0.06 g, 0.564 
mmol) in anhydrous DCM (10 ml) was added 2 (0.08 g, 0.564 mmol). The resulting solution was 
allowed to stir for 4h at rt. The reaction mixture was then washed with brine (3 x 50 mL) and the 
organic layer dried over anhydrous Na2SO4 and concentrated in vacuo. Purification by flash 
chromatography (Et3N/MeOH/EtOAc = 1/10/89) yielded the protected intermediate which was 
taken directly to the next step without further characterization. Starting from the protected 
intermediate, CH3CN (2 ml), H2O (2 ml) and TFA (1.36 ml) were added to the reaction mixture. 
The resulting solution was allowed to stir overnight at rt. The volatiles were then removed in 
vacuo and the reaction mixture was subjected to reverse phase chromatograph, followed by 
lyophilization yielding 3 as a white solid (0.13 g, 35%). 
1
H NMR(D2O, 300 MHz): δ3.73(d, J = 
5.7 Hz, 2H), 4.12(m, 2H), 4.32(m, 1H), 5.65(d, J = 3.3 Hz, 1H), 6.11(d, J = 7.8 Hz, 1H), 7.85(d, 
J = 8.1 Hz, 1H), 8.24(dd, J = 6.9, 1.5 Hz, 2H), 8.85(dd, J = 6.9, 1.2 Hz, 2H). 
13
C NMR (D2O, 
300 MHz): δ41.63, 70.55, 73.23, 81.77, 92.36, 94.90, 125.35, 142.41, 144.96, 148.04, 150.13, 
159.16, 165.56. Anal. Calcd. for C15H17N5O5• 2.5CF3COOH• H2O: C, 36.93, H, 3.33, N, 10.77. 






ran-2-yl)methyl)-2-(imidazo[2,1-b]thiazol-6-yl)acetamide (4): To a solution of 1 (0.30 g, 
0.513 mmol) and Et3N (0.05 g, 0.513 mmol) in DMF (2 ml) was added a solution of HOBT (0.09 
g, 0.513 mmol), HBTU (0.19 g, 0.513 mmol) and imidazo[2,1-b]thiazole-6-acetic acid (0.09 g, 
0.513 mmol)in DMF (3ml). The resulting solution was allowed to stir overnight at rt. 
Purification by flash chromatography (Et3N/MeOH/EtOAc = 1/10/89) yielded protected 
intermediate which was taken directly to the next step without further characterization. Started 
from the protected intermediate, CH3CN (2.5 ml), H2O (2.5 ml) and TFA (2 ml) were added to 
the reaction mixture. The resulting solution was allowed to stir overnight at rt. The volatiles were 
removed in vacuo and the reaction mixture was subjected to reverse phase chromatograph, 
followed by lyophilization yielding 4 as a light yellow solid (0.19 g, 58%). 
1
H NMR(CD3OD, 
300 MHz): δ3.60 (dd, J = 6.3, 4.8 Hz, 2H), 3.83 (s, 2H), 4.04 (m, 2H), 4.29 (dd, J = 5.6, 3.6 Hz, 
1H), 5.73 (d, J = 3.6 Hz, 1H), 6.11 (d, J = 7.8 Hz, 1H), 7.54 (d, J = 4.2 Hz, 1H), 7.91 (s, 1H), 
8.02 (d, J = 4.2 Hz, 1H), 8.06 (d, J = 8.1 Hz, 1H). 
13
C NMR (CD3OD, 300 MHz): δ32.03, 40.98, 
70.91, 73.61, 82.66, 92.78, 93.59, 113.35, 117.18, 121.06, 134.29, 145.67, 147.37, 147.55, 
160.11, 169.08. Anal. HPLC (RetTime: 2.0 min, Area%:97%). 
 
N-(((2R,3S,4R,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-3,4-dihydroxytetrahydrofuran-2-
yl)methyl)imidazo[2,1-b]thiazole-6-carboxamide (5): To a solution of 1 (0.25 g, 0.428 mmol) 
and Et3N (0.04 g, 0.428 mmol) in DMF (2 ml) was added a solution of HOBT (0.07 g, 0.428 
mmol), HBTU (0.16 g, 0.428 mmol) and imidazo[2,1-b]thiazole-6-carboxylic acid (0.07 g, 0.428 





flash chromatography (Et3N/MeOH/EtOAc = 1/10/89) yielded protected intermediate which was 
taken directly to the next step without further characterization. Starting from the protected 
intermediate, CH3CN (2.5 ml), H2O (2.5 ml) and TFA (2 ml) was added to the reaction mixture. 
The resulting solution was allowed to stir overnight at rt. The volatiles were removed in vacuo 
and the reaction mixture was subjected to reverse phase chromatograph, followed by 
lyophilization yielding 5 as a white solid (0.19 g, 71%). 
1
H NMR(CD3OD, 300 MHz): δ3.72 (dd, 
J = 14.4, 6.6 Hz, 1H), 3.82 (dd, J = 14.4, 6.6 Hz, 1H), 4.09 (overlap dd, J = 5.4 Hz, 1H), 4.18 
(dd, J = 10.5, 4.8 Hz, 1H), 4.31 (overlap dd, J = 5.1, 3.6 Hz, 1H), 5.75 (d, J = 3.6 Hz, 1H), 6.10 
(d, J = 7.8 Hz, 1H), 7.38 (d, J = 4.5 Hz, 1H), 8.00 (s, 1H), 8.11 (d, J = 7.8 Hz, 1H), 8.34 (d, J = 
4.5 Hz, 1H). 
13
C NMR (CD3OD, 300 MHz): δ 40.41, 70.91, 73.69, 82.90, 92.51, 93.59, 115.49, 
120.79, 124.89, 127.80, 128.51, 134.42, 145.43, 147.59, 160.05, 160.15. Anal. HPLC (RetTime: 
2.1 min, Area%: 94%). 
 
N-(((2R,3S,4R,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-3,4-dihydroxytetrahydrofuran-2-
yl)methyl)thiazole-4-carboxamide (6): To a solution of 1 (0.25 g, 0.428 mmol) and Et3N (0.04 
g, 0.428 mmol) in DMF (2 ml) was added a solution of HOBT (0.07 g, 0.428 mmol), HBTU 
(0.16 g, 0.428 mmol) and 4-thiazolecarboxylic acid (0.06 g, 0.428 mmol) in DMF(3ml). The 
resulting solution was allowed to stir overnight at rt. Purification by flash chromatography 
(Et3N/MeOH/EtOAc = 1/10/89) yielded protected intermediate which was taken directly to the 
next step without further characterization. Started from the protected intermediate, CH3CN (1.5 
ml), H2O (1.5 ml) and TFA (1.3 ml) was added to the reaction mixture. The resulting solution 





was subjected to  reverse phase chromatograph, followed by lyophilization yielding 6 as a white 
solid (0.10 g, 40%). 
1
H NMR(CD3OD, 300 MHz): δ3.70-3.87 (m, 2H), 4.05 (overlap dd, J = 5.7 
Hz, 1H), 4.20 (overlap dd, J = 6 Hz, 1H), 4.26 (overlap dd, J = 5.1 Hz, 1H),  5.80 (d, J = 3.6 Hz, 
1H), 6.10 (d, J = 7.8 Hz, 1H), 8.18 (d, J = 7.8 Hz, 1H), 8.29 (s, 1H), 9.03 (s, 1H). 
13
C NMR 
(CD3OD, 300 MHz): δ 40.53, 71.03, 73.98, 82.79, 91.75, 93.74, 123.80, 144.71, 148.76, 150.25, 
154.18, 160.83, 162.45. Anal. HPLC (RetTime: 2.1 min, Area%:97%). 
 
N-(((2R,3S,4R,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-3,4-dihydroxytetrahydrofuran-2-
yl)methyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide (7): To a solution of 1 (0.30 g, 0.513 
mmol) and Et3N (0.05 g, 0.513 mmol)in DMF (2 ml) was added a solution of HOBT (0.09 g, 
0.513 mmol), HBTU (0.19 g, 0.513 mmol) and 3H-Imidazo[4,5-b]pyridine-7-carboxylic acid 
(0.08 g, 0.513 mmol) in DMF (3 ml). The resulting solution was allowed to stir overnight at rt. 
Purification by flash chromatography (Et3N/MeOH/EtOAc = 1/10/89) yielded protected 
intermediate which was taken directly to the next step without further characterization. Started 
from the protected intermediate, CH3CN (2.5 ml), H2O (2.5 ml) and TFA (2 ml) was added to the 
reaction mixture. The resulting solution was allowed to stir overnight at rt. The volatiles were 
removed in vacuo and the reaction mixture was subjected to reverse phase chromatograph, 
followed by lyophilization yielding 7 as a light yellow solid (0.10 g, 32%). 
1
H NMR(CD3OD, 
300 MHz): δ3.90-3.95 (m, 2H), 4.14 (t, J = 4.8 Hz, 1H),  4.25 (t, J = 4.4 Hz, 1H), 4.32 (overlap 
dd, J = 5.3, 3.5 Hz, 1H), 5.8 (d, J = 3.5 Hz, 1H), 6.07 (s, J = 7.8 Hz,1H), 7.9 (d, J = 5.1 Hz, 1H), 










 As described previously for the fusion series (see page 22), the fusion compounds were 
generated based upon the combination of hit molecules that bind to two pockets from the active 
site of BpIspF.  This can be considered a fragment linking approach in the development of lead 
molecules, during the elaboration cycle of inhibitor discovery.
11
 Alternatively, fragment growing 
can also be employed as a reasonable method for the generation of lead molecules by expanding 
fragment hits through synthetic efforts.
11
  Generally, the fragment growing method involves the 
identification of a desired hit, and rational developments upon the structure of the hit are 
performed with careful consideration of synthetic tractability. Since the structures of the hits for 
the cytidine pocket is fairly conserved (all hits contain a cytosine moiety), we started to explore 
the possibility of zinc binding molecules. With various fragment hits for the zinc pocket (shown 
in Figure 3), we chose FOL955 as a possible candidate for the fragment growing method because 
it could provide greater diversity of the resulting lead molecules and allows greater flexibility 
concerning compound synthesis.   
 In the pursuit of novel inhibitors via the fragment growing method, structural information 
concerning the initial hit molecules bound to the inhibitory site is crucial for the development of 
lead molecules. Analysis of the X-ray crystal structure of FOL955 bound to BpIspF (PDB: 
3QHD) offered insight into the design of new molecules (Figure 8). FOL955 binds to the zinc 
through the nitrogen in the aromatic system and the phenol creates hydrogen binding with the 





found the hydrophobic pocket, same to that discovered earlier for the fusion molecules, which is 
created by residues Ile59, Phe63 and Leu78 in close proximity to the zinc pocket. This secondary 
pocket can undergo potential reorientation to accommodate larger hydrophobic groups, which is 
reported in various crystal structures of BpIspF
16
. To further elaborate the strategy of the 
fragment growing method, we proposed two directions for the development of the fragment 
FOL955: (1) Based on the hypothesis that interactions with the extra hydrophobic pocket could 
potentially increase the affinity of the lead molecules, we can design a library of potential lead 
compounds,  utilizing FOL955 as the core coupled with functional groups capable of fitting in 
the hydrophobic pocket, (2) The installation of groups pointing towards the cytidine pocket 
occupied by FOL955 can provide a good starting point for fragment growth, presumably by 
manipulating hydrogen binding to residues within the cytidine pocket. With no literature 
evidence of molecules bound to residues within the hydrophobic pocket, we decided to choose 
the second direction discussed above for fragment growth, while also considering the synthetic 
accessibility of the designed compounds and the reported interactions (PDB: 3KE1) within the 
cytidine pocket. To pursue our hypothesis, imidazole analogs were synthesized in which the N1 
of FOL955 was moved to the N5 position of the imidazole ring for synthetic ease (Figure 9).  
This analog permitted the synthesis of many compounds by varying the R groups to test for 
binding affinity without affecting the ability of N3 to coordinate with the catalytic zinc ion in the 





















Synthesis of imidazole compounds 
 
 The synthesis of the imidazole analogs was achieved via a similar synthetic pathway to 
published procedures (Scheme 3).
28,29
 A mixture of MgSO4, triethyl amine and the corresponding 
aromatic amine was stirred at room temperature for 1h, and 4-hydroxy benzaldehyde was added 
and refluxed for 4 h to afford the corresponding imine. After the solvent was concentrated under 
reduced pressure, MeOH, K2CO3 and TosMIC reagent were added, and the mixture was refluxed 








Structure activity relationship (SAR) analysis 
 
 Initial SPR binding studies showed low affinity (KD > 2 mM) of FOL 955 (determined by 
Joy Blain). The increasing affinity of the synthesized imidazole compounds compared to 
FOL955 provides promising evidence for our fragment growing method. In order to generate 





to the SPR assay against BpIspF to determine their KD, with L-tryptophan hydroxamate as an 



























8 FOL955 >2000 > 40 > 40 > 40 
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>2000 > 40 > 40 > 40 
10 
 
>2000 > 40 > 40 > 40 
11 
 
>2000 >40 >40 >40 
12 
 
>2000 9.8 12.9 7.9 
13 
 
>2000 11.5 13.8 7.2 
14 
 
90 1.7 3.4 0.59 
15 
 
>2000 >40 >40 >40 
16 
 
1350 11.3 13.3 13.6 
17 
 





 As shown in Table 2, all the imidazole analogs ranged in binding affinity from 55 μM to 
greater than 2000 μM. Additionally, the initial screening at 50 μM offered a scatter diagram 
which provided the correlation between the compound number and response values (Figure 8). 
We can easily separate the compounds into three groups of imidazole analogs; including weak (< 
30 µRU), excess (> 140 µRU), and ideal target (30-140 µRU) responses. The weak response 
group sets a lower limit estimate for KD values of > 200 μM while several compounds within the 
excess group indicated the non-specific binding interactions with BpIspF and / or poor solubility 
due to the fact of exceeding the calculated maximum µRU value. The remainder of the 
compounds gave ideal KD between 20-200 μM which provided us with compounds for 
reasonable SAR analysis. 
 Moreover, anti-malarial activity was measured by using three different strains of P. 
falciparum as shown in Table 3. As previously described,
25
 these three strains of the P. 
falciparum parasites are W2 (chloroquin (CQ) resistant, mefloquine (MFQ) sensitive), D6 (CQ 
susceptible, MFQ resistant) and C235 (multidrug resistant, CQ, pyrimethamine). The efficacies 
ranged from 0.59 μM to greater than 40 μM.  Based upon the observed SAR a conclusion was 
made: Substitution of the imidazole nitrogen with 1 or 2 carbon linkers bearing a heteroaromatic 
or haloaromatic group result in compounds with IspF affinity and antimalarial efficacy.   
Functional assay of imidazole analogs in P. falciparum 
 
 In order to confirm that the anti-malarial efficacy was a function of IspF inhibition, 
selected imidazole analogs were tested by our collaborator, Dr. Audrey Odom.  A high pressure 
liquid chromatography-mass spectrometry (HPLC-MS/MS) based assay was used to confirm the 





analogs 14 and 17 (Figure 10). The concentration of three enzymatic products from the MEP 
pathway was evaluated. Decreasing concentration of MEcPP was observed for both compounds, 
which indicated that imidazole analogs can interfere in the functionality of IspF by controlling 
the level of metabolite. Interestingly, compound 17 showed an unexpected inhibition on the 
upstream metabolite, DOXP, which is involved in the biosynthetic pathway of DXS. We are 
currently collaborating with Dr. Odom to further study the mechanism of action of the imidazole 
compounds against DXS, IspD, and IspF, and to investigate the selectivity of the inhibitors.   
 























Structural analysis of compound 16 
 
 To further evaluate the designing strategy of imidazole compounds, crystal structure of 
compound 16 in BpIspF was obtained (by Dr. Darren Begley). As shown in figure 11, compound 
16 remains hydrogen bonding with side chain of Phe63, Asp65 and the nitrogen atom on the 
imidazole ring coordinates to the zinc atom. The furan moiety orients toward the cytidine pocket 
and has a potential to fit in the ribose binding area. Future development will focus on 
modification of the furan ring in order to either create hydrogen bonding with Asp58 or obtain 
analogs that have optimized interactions with the cytidine pocket.  
 
 











 Based upon the fragment hit FOL955, which displayed poor affinity for the IspF enzyme, 
lead molecules from the imidazole series were synthesized that displayed micromolar binding 
affinity. These lead molecules demonstrated antimalarial efficacy against three strains of drug 
resistant P. falciparum.  The discovered leads from the imidazole series have potential for further 
lead optimization against drug-resistant malaria strains. In addition, the HPLC-MS/MS results 
demonstrated for the first time that the antimalarial efficacy was through regulation of the level 
of MEcPP in cells. The functional relevance of these compounds to the in vivo assay provides 
promising evidence for MEP pathway inhibition and regulation. In summary, the fragment 
growing method was successfully applied in the development of the imidazole series of 
inhibitors against IspF and afforded a compound library for future study. We are currently 
working on the fragment growing method of other chemical motifs, which involves investigating 
interactions with the hydrophobic pocket in order to increase the diversity of the imidazole 




 All commercially available reagents were used without further purification. Column 
chromatography was performed on silica gel (230−400 mesh) and Biotage Isolera One. 1H NMR 
and 13C NMR spectra were recorded on Avance III 300 MHz NMR (Bruker Biospin from 
Billenca, using BBFO probe, 5 mm). IR spectra were recorded on Mattson Gausis ATI FT-IR 





USA. Analytical HPLC were recorded on an Agilent 1100 HPLC system using a C-18 column 
and 90:10 water(0.1% TFA) to acetonitrile ->10:90 water (0.1% TFA) to acetonitrile over 40 
minutes Analytical HPLC were recorded on an Agilent 1100 HPLC system using a C-18 column 
(Waters Nova-Pak 3.9 x 150 mm) with the following gradient: 90:10 water(0.1% TFA) to 
acetonitrile to 10:90 water (0.1% TFA) to acetonitrile over 40 minutes. Samples were monitored 
at 254 and 280 nm. CHN analysis was recorded on Perkin Elmer Series II CNH analyzer. 
 
Surface plasmon resonance  
 
 SPR binding experiments were performed on a Reichert SR7000DC (with a SR7500DC 
upgrade) using a high density 500,000 Da carboxymethyl dextran SR7000 gold sensor slide. IspF 
was coupled to the sensor slide using amine coupling chemistry. Initially, the surface was 
activated by injecting a mixture of 75 mg/ml EDC (N-Ethyl-N′-(3-dimethylaminopropyl) 
carbodiimide hydrochloride) and 11.5 mg/ml NHS (N-hydroxysuccinimide) for 7 min using a 50 
μl/min flow rate.  IspF, diluted in 10 mM 4.5 pH sodium acetate buffer at a final concentration of 
120 μg/ml, was injected over the surface for 7 min at 30 μl/min. Excess succinamide ester groups 
were quenched with an injection of 1M ethanolamine for 3 min with a 50 μl/min flow rate. A 
total of 4000-8000 μRIU (Refractive index units) of IspF were coated on the slide. Binding 
experiments were conducted at 20°C in 50 mM sodium phosphate pH 7.4/150 mM NaCl/4.76% 
DMSO at 50 μl/ min. Initially, compounds were dissolved in DMSO at 4 mM and were diluted 
(20-fold) into 50 mM sodium phosphate pH 7.4/150 mM NaCl, to produce a 200 μM compound 
sample with 4.76% DMSO, thereby minimizing buffer mismatch. A concentration series of 





over the IspF surface. Blank (Buffer-only) injections were included between each compound 
injection, allowing for double subtraction (reference cell and buffer) during data processing. Data 
processing and analysis was performed using Scrubber (BioLogic Software).  
 
Malaria parasite culture 
 
 P. falciparum strain 3D7 was cultured at 37°C in a 2% suspension of human erythrocytes 
in RPMI-1640 medium (Sigma-Aldrich, SKU R4130) supplemented with 27 mM sodium 
bicarbonate, 11 mM glucose, 5 mM HEPES, 1 mM sodium pyruvate, 0.37 mM hypoxanthine, 
0.01 mM thymidine, 10 µg/mL gentamicin, and 0.5% Albumax (Life Technologies) in a 5% O2/ 
5% CO2 / 90% N2 atmosphere, as previously described. 
6,30
 Culture growth was monitored by 
microscopic analysis of Giemsa-stained blood smears. 
 
Metabolic profiling of MEP pathway intermediates 
 
 P. falciparum strain 3D7 was cultured in 75 mL volumes in 150 mm × 25 mm tissue 
Culture dishes at 4% hematocrit until >6% parasitemia was reached. Cultures were synchronized  
by 1-2 treatments with 5% sorbitol until >8% parasitemia and >75% of parasites were in ring 
stage growth. Once these criteria were met, 75 mL cultures were split into 3 × 25 mL samples. 
Ring stage cultures were then treated +/- 5 µM FSM (Life Technologies) for either 0 h or 10 h. 
At each time point, parasite-infected erythrocytes were lysed with 0.1% saponin, the parasite 
pellets washed with PBS, and the pellets stored at -80°C until extraction. Samples were extracted 






General procedure for the synthesis of imidazole analogs 
 
 Novel compounds were synthesized similarly to reported methods
28,29
 A mixture of the 
corresponding primary amine (3.41 mmol), MgSO4 (1.03 g, 8.53 mmol) and triethylamine (3.1 
mL) was stirred at room temperature for 1 hour. Then, 4-hydroxybenzaldehyde (0. 415 g, 3.40 
mmol) was added, and the mixture was refluxed at 90
o
C for 4 hours. The reaction mixture was 
filtered using section filtration, and the precipitate was washed with 10 ml Et3N followed by 10 
mL anhydrous MeOH, and the solvents were removed under vacuum. 
 The concentrated mixture of the imine was re-dissolved in anhydrous MeOH (6 mL).  
TosMIC (p-toluenesulfonyl) methyl isocyanide (0.860 g, 4.43 mmol) and K2CO3 (1.41 g, 10.2 
mmol) were added, and the mixture was refluxed at 65
o
C for 2 hours. The solvent was removed 
under vacuo, and the crude was partitioned between EtOAc (20 mL) and water (20 mL). The 
aqueous layer was extracted two times with EtOAc (2 x 20 ml). The combined organic layers 
were washed with brine (30 mL) and dried with anhydrous Na2SO4 (about 3 g), and the solvent 
was removed at reduced pressure. The crude was chromatographed by Biotage (DCM:MeOH) to 
afford the corresponding imidazole analogue. For surface Plasmon resonance (SPR) test, 
compounds were converted to the corresponding hydrogen chloride salts by adding two 
equivalents of HCl in dioxane. The formation of the salt was confirmed by a downfield chemical 
shift of imidazole protons (see the proton NMR of the salts). 
4-(1-isopropyl-1H-imidazol-5-yl)phenol (9): 
The desired product was collected as a light yellow solid (0.59 g, 56.7% yield). mp 170 - 175 °C. 
1





0.9 Hz, 1H), 6.88 (d, J = 8.4 Hz, 2H), 7.20 (d, J = 8.4 Hz, 2H), 7.84 (d, J = 1.2 Hz, 1H); 
13
C 
NMR (75 MHz, CD3OD): δ 22.54, 46.91, 115.21, 120.60, 125.37, 130.56, 132.97, 133.95, 
157.71. Anal. HPLC (Ret time: 1.9 min, Area%: 99%). Anal. Calcd for C12H14N2O  • 0.3H2O: C, 
69.41; H, 7.09; N, 13.49; Found: C, 69.80; H, 6.98; N, 13.25.  
 
4-(1-benzyl-1H-imidazol-5-yl)phenol (10): 
The desired product was collected (0.46 g, 66.6% yield) as a light yellow solid. mp 156 -  
159 °C. 
1
H NMR (300 MHz, CD3OD):  δ 5.22 (s, 2H), 6.79 (d, J = 8.7 Hz, 2H), 6.95 (d, J = 1.2  
Hz, 1H), 6.98 (dd, J = 7.8, 2.1 Hz, 2H), 7.11 (d, J = 8.7 Hz, 2H), 7.26-7.29 (m, 3H), 7.76 (d, J =  
0.9 Hz, 1H); 
13
C NMR (75 MHz, CD3OD): δ 48.23, 115.09, 120.20, 125.91, 126.49, 127.40,  
128.37, 130.24, 133.77, 137.99, 157.64. Anal. HPLC (Ret time: 2.6 min, Area%: 99%). Anal. 
Calcd for C16H14N2O  • 0.6H2O: C, 73.60; H, 5.87; N, 10.73. Found: C, 73.85; H, 5.51; N, 10.76.  
 
4-(1-(4-chlorophenethyl)-1H-imidazol-5-yl)phenol (14) 
The desired product 17 was collected as a yellow solid (0.23 g, 46.2% yield). mp 150 - 155°C. 
1
H NMR (300 MHz, CD3OD): δ 2.81 (t, J = 6.9 Hz, 2H), 4.27 (t, J = 6.9 Hz, 2H), 6.84 (s,1H), 
6.86 (d, J = 6.0 Hz, 2H), 6.89 (d, J = 5.4 Hz, 2H), 7.15 (d, J = 8.4 Hz, 2H), 7.19 (d, J = 8.4 Hz, 
2H), 7.48 (s, 1H); 
13
C NMR (75 MHz, CD3OD): δ 35.76, 46.09, 115.23, 120.45, 125.77, 128.15, 
129.95, 130.07, 132.19, 133.28, 136.42, 137.64, 157.65.  Anal. HPLC (Ret time: 4.8 min, 
Area%: 99%). Anal. Calcd for C17H15ClN2O • 0.2H2O: C, 67.53; H, 5.13; N, 9.26; Found: C, 







The desired product 18 was collected as a yellow solid (0.30 g, 48.1% yield). mp: 225 - 228°C. 
1
H NMR (300 MHz, CD3OD): δ 2.72 (t, J = 6.9 Hz, 2H), 4.18 (t, J = 6.9 Hz, 2H), 6.64 (d, J = 8.7 
Hz, 2H), 6.74 (d, J = 8.7 Hz, 2H), 6.84 (d, J = 0.9 Hz, 1H), 6.88 (d, J = 8.7 Hz, 2H), 7.16 (d, J = 
8.7 Hz, 2H), 7.44 (d, J = 1.2 Hz, 1H); 
13
C NMR (75 MHz, CD3OD): δ 35.67, 46.68, 114.88, 
115.19, 120.61, 125.61, 128.32, 129.32, 130.16, 133.26, 137.59, 155.87, 157.58. Anal. HPLC 
(Ret. time: 2.2 min., Area%: 99%). Anal. Calcd for C17H16N2O2  • 0.2H2O: C, 71.91; H, 5.82; N, 
9.87; Found: C, 72.04; H, 6.04; N, 9.90. 
 
4-(1-(furan-2-ylmethyl)-1H-imidazol-5-yl) phenol (16) 





H NMR (300 MHz, CD3OD) δ 5.16 (s, 2H), 6.14 (dd, J = 3.3, 0.6 Hz, 1H), 6.34 (dd, J 
= 3.0, 1.8 Hz, 1H), 6.87 (d, J = 8.7 Hz, 2H), 6.90 (d, J = 1.2 Hz, 1H), 7.22 (d, J = 8.7 Hz, 2H), 
7.45 (dd, J = 1.8, 0.9 Hz, 1H), 7.71 (d, J = 0.9 Hz, 1H);
 13
C NMR (75 MHz, CD3OD) δ 41.25, 
108.30, 110.14, 115.18, 120.03, 125.56, 130.38, 133.53, 137.59, 142.82, 149.70, 157.74. Anal. 
HPLC (Ret. time: 2.0 min., Area%: 99%). Anal. Calcd for C14H12N2O2 • 0.2H2O: C, 68.95; H, 
5.13; N, 11.49; Found: C, 69.07; H, 5.09; N, 11.42. 
4-(1-(2-(1H-indol-3-yl)ethyl)-1H-imidazol-5-yl)phenol (17) 
The desired product 23 was collected as a yellow solid (0.23 g, 77.2%). mp: 210 - 215°C. 
1
H 





6.92-6.97 (m, 1H), 7.05-7.08 (m, 1H), 7.13 (d, J = 8.7 Hz, 2H), 7.19 (d, J = 7.8 Hz, 1H), 7.30 (d, 
J = 9 Hz, 1H), 7.48 (s, 1H); 
13
C MNR (75 MHz, CD3OD): δ 26.64, 45.71, 110.26, 110.84, 
115.19, 117.56, 118.36, 120.99, 122.45, 125.53, 126.95, 130.27, 133.30, 136.62, 137.49, 157.56. 
Anal. HPLC (Ret. time: 3.7 min, Area%: 99%). Anal. Calcd for C19H17N3O • 0.3H2O: C, 73.91; 
H, 5.75; N, 13.61. Found: C, 74.04; H, 5.73; N, 13.68. 
 
 




 We designed our fusion and imidazole series of lead compounds based on the fragment 
based drug discovery theory. In contrast, other chemical series can also provide us with different 
methods of lead molecule design which does not follow with the theory of  fragment linking 
(fusion series) and fragment growing  (imidazole series). 
 In our research, coordination of lead molecules to the zinc binding site has been 
demonstrated to be important. It is well known that matrix metalloprotease (MMP) inhibitors 
bind to zinc in the catalytic site of MMP, such inhibition is responsible for numerous biological 
activities.
31
 The general structure of the MMP includes a three histidine residues-bound zinc in 
the conserved active site.
32
 A typical MMP inhibitor should contains a peptidomimetic backbone 







Figure 12 Typical binding model of varies MMP   
 
 In collaboration with Dr. Michael Clare at Emerald Biostructures, we initiated the design 
of a new chemical series that shares a similar binding strategy with known MMP inhibitors. As a 
result, the chelate structures, which contain 5 or 6 member ring systems, had been generated and 
the pyrimidine series became our primary target to study (Figure 13). Hypothetically, the 
pyrimidine derivatives will bind to the zinc through both the carbonyl group on the aromatic ring 
and the carboxylic acid functional group. Unlike the fusion and imidazole series, no crystal 
structure of pyrimidine bound to BpIspF was reported which increases the difficulty of the lead 
compound design. In order to collect the preliminary data on this chemical series, we decided to 
synthesize several analogs which contained the pyrimidine core as well as substituents similar to 
the imidazole series, as described previously. Additionally, the combination of SPR and anti-











Figure 13 Design of pyrimidine series as zinc-binding molecules 
 
Synthesis of pyrimidine series 
 
 The pyrimidine core 18 was built by Michael addition of S-methyl isothiourea with 
diethyl 2-(ethoxymethylene) malonate followed by cyclization. The resulting pyrimidine was 
treated with a variety of amines to obtain final products (Scheme 4). Compound 19 was 
synthesized by the same nucleophilic substitution with 4-iodoamine followed by a Suzuki 
coupling. Additionally, sodium salts were made for all the ester products in order to increase 
their solubility for SPR assay.  
 
 





 Scheme 5 Synthesis of pyrimidine compound 19 
 
SPR, anti-bacterial, anti-malarial and herbicidal assay 
 
 In general, the compounds of the pyrimidine series exhibit limited aqueous solubility 
when performing the SPR assay. In order to overcome these solubility limitations, Sriram 
Jakkareju as one of our group members optimized the buffer condition for the SPR assay of 
BpIspF. Two compounds (compound 19 and 24) as sodium salts were found to exhibit 
reasonable log curves and showed KD values of 16 and 305 µM respectively. (Figure 14 and 15)  
Additionally, Dr. Matthew Byrd at the University of Carolina at Chapel Hill offered us an 
opportunity to screen pyrimidine compounds against Burkholderia pseudomallei. In this assay, a 
series of pyrimidine compounds were tested, with only one, compound 24 (structure shown in 
Table 3), exhibiting activity against Burkholderia pseudomallei at 1mM concentration. The 
activity of compound 24 was then compared to that of Kanamycin at 300 μg/ml (Kan300), a 
triazole compound (synthesized by Phumvadee Wangtrakuldee from our group), nitroxoline and 






Figure 14 Log curve and SPR result of compound 19 
 
Figure 15 Log curve and SPR result of compound 24 
 Figure 16 shows the inhibition of B. pseudomallei by each compound (at 1 mM) along 
with a blank and Kanamycin as negative control, which completely inhibits the growth of the 





which are known to be effective antibiotics. Furthermore, a dose-response curve was generated 
for compound 24 and decreasing activity was observed when the concentration of inhibitor was 
lower than 1 mM (Figure 17). 
 
 
Figure 16 Anti-bacterial activity of compound 24 (HGN-0028, showed as orange line) against 
Burkholderia pseudomallei at 1mM. 
 
The pyrimidine compounds were also tested in the anti-malarial assay against three drug-
resistant strains of P. falciparum (Table 3). Only two of the pyrimidine compounds (32 and 37) 
showed activity against all three strains, which might be due to the solubility limitation of the 







Figure 17 A dose-response curve of compound 24. 
 
 We also collaborated with Dr. Illarionov at the University of Hamburg in Germany to 
obtain the activity of the pyrimidine compounds against IspF from Arabidopsis thaliana. 
Compounds 21, 24, 29, 30, and 36 showed high micromolar activity which provided an 
alternative application of the pyrimidine series as potential herbicidal agents (Table 4). Since the 
MEP pathway is found in higher order plant species and considering the limitation on current 
herbicidal agents, future exploration of pyrimidine series as inhibitors of plant IspF will afford 
more scientific interest on our research and expand the diversity on designing MEP inhibitors. 
Pyrimidine analogs as IspE inhibitors  
 
 IspE is a unique enzyme compared to IspD and IspF because it is a kinase which 
catalyzes the ATP- and Mg
2+






give 4-diphosphocytidyl-2C-methyl-D-erythritol 2-phosphate (CDP-ME2P).
33
 Computational 
modeling of E. coli IspE with CDP-ME and ATP-analog adenosine-5’-(γ-imino) triphosphate as 
a complex (PDB: 1OJ4) provides structural information of the active site. With assistance of 
MOLOC docking software, Dr. Diederich reported the result of compound 38 in the active site of 
Escherichia coli IspE.
33-36
 Generally, the cytosine moiety of the inhibitor forms a sandwich type 
structure including Phe185 and Tyr25 (π-π stacking) with additional hydrogen binding 
interactions to the backbone and the side-chain of His26. Additionally, the sulfonamide moiety 
creates important hydrogen bonding to Lys10, Asn12 and Asp141 (Figure 18). Guided by this 
docking result, docking was performed on the Sybyl software for compound 38 with two 
compounds from the pyrimidine series in order to investigate their possible binding pattern 
within the active site. Fortunately, the same sandwich type of structure was observed  for the 
cytosine moiety of the sample inhibitor although the sulfonamide did not make any hydrogen 
bonding with the amino acid residues, which might result from the different algorithm used for 
Sybyl vs MOLOC (Figure 19). Interestingly, our pyrimidine compounds 24 and 33 formed a 
similar π-π stacking interaction with Phe185 and Tyr25. Additionally, hydrogen bonding was 
observed for the pyrimidine core to His26 (Figure 20 and 21). Moreover, the results from the 
University of Hamburg show micromolar activity of pyrimidine series against Solanum 
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Figure 19 Docking result of compound 38 in the active site of E. coli IspE (PDB: 1OJ4, performed by 







Figure 20 Docking result of 24 in the active site of E. coil IspE 
 






 With no literature precedent concerning the binding of pyrimidine compounds to IspE, it 
is possible to apply docking software for this series generate a hypothetical binging pattern and 
re-evaluate our future direction. Docking results (Figure 19 and 20) showed the pyrimidine core 
preferably also formed a sandwich type of structure with Phe185 and Tyr25. Either the nitrogen 
on the pyrimidine ring or the oxygen of carbonyl group interacted with His26 through hydrogen 
bonding. The difference in the orientation of the ester group was due to the energy minimization 
performed by SYBYL. Despite the lack of a co-crystalline structure of pyrimidine compounds 
bond to the active site of E. coli IspE, computational modeling can still afford us a general idea 
of the potential binding interactions and provide a theoretical support for the affinity of 




 Pyrimidine compounds were successfully generated based on the MMP inhibitors and the 
results of anti-bacterial, anti-malarial, herbicidal assay were collected. Docking analysis of 29 
and 33 provided a hypothesis of pyrimidine compound binding to the active site of EcIspE. 
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General method for preparing pyramiding compounds 19-37 
 A mixture of ethyl 2-(methylthio)-6-oxo-1, 6-dihydropyrimidine-5-carboxylate and 
various amine (1 eq) was heated under neat condition for 15 h.  After cooling the reaction 
mixture to room temperature, the solid residue was washed with 5 ml of ethanol for 15 min and 
collected via vacuum filtration. 
Surface plasmon resonance 
 SPR binding experiments were performed on a Reichert SR7000DC (with a SR7500DC 
upgrade) using a high density 500,000 Da carboxymethyl dextran SR7000 gold sensor slide. IspF 
was coupled to the sensor slide using amine coupling chemistry. Initially, the surface was 
activated by injecting a mixture of 75 mg/ml EDC (N-Ethyl-N′-(3-
dimethylaminopropyl)carbodiimide hydrochloride) and 11.5 mg/ml NHS (N-
hydroxysuccinimide) for 7 min using a 50 μl/min flow rate.  IspF, diluted in 10 mM 5.0 pH 
sodium acetate buffer at a final concentration of 120 μg/ml, was injected over the surface for 10 
min at 30 μl/min. Excess succinamide ester groups were quenched with an injection of 1M 
ethanolamine for 6 min with a 50 μl/min flow rate. A total of 4000-7500 μRIU (Refractive index 
units) of IspF were coated on the slide. Binding experiments were conducted at 20°C in 50 mM 
sodium phosphate pH 7.4/150 mM NaCl/4.76% DMSO at 50 μl/ min. Initially, compounds were 
dissolved in DMSO at 20 mM and were diluted (20-fold) into 50 mM sodium phosphate pH 
7.4/150 mM NaCl, to produce a 1 mM compound sample with 4.76% DMSO, thereby 





using running buffer) was generated and injected over the IspF surface. Blank (Buffer-only) 
injections were included between each compound injection, allowing for double subtraction 
(reference cell and buffer) during data processing. Data processing and analysis was performed 
using Scrubber (BioLogic Software). 
 
Ethyl 2-(methylthio)-6-oxo-1,6-dihydropyrimidine-5-carboxylate (18) 
To a stirred solution of diethyl 2-(ethoxymethylene)malonate (5.0 g, 0.023 mol) and S-
methylisothiourea hemisulfate salt (1.5 eq) in H2O (40 mL) was added KOH solution (3.25 g 
KOH pellets in 10 ml H2O) dropwise in an ice-water bath. The reaction was first stirred for 1h at 
0
o
C and then warmed up to room temperature overnight.  The initial precipitate was removed by 
filtration and the pH of the filtrate was adjusted to 3 with 2 M HCl solution. The filtrate was 
stirred for 1h and the resulting white precipitate was collected by filtration and recrystallized 
from toluene (10 mL)to yield ethyl 2-(methylthio)-6-oxo-1,6-dihydropyrimidine-5-carboxylate 1 
(2.56 g, 52% yield). 
1
H NMR (300 MHz, DMSO-D6): δ 1.25 (t, J = 7.2 Hz, 3H); 2.53 (s, 3H), 
4.20 (q, J = 6.9 Hz, 2H); 8.44 (s, 1H-pyrimidine); Anal. HPLC: Ret. Time: 2.5 min, Area%: 
92%; Anal. Calcd for C8H10N2O3S • 0.15H2O:  C: 44.29, H: 4.79, N: 12.91; Found: C: 44.62, H: 
4.57, N: 12.42. 
Ethyl 6-oxo-2-((4-(pyridin-4-yl)phenyl)amino)-1,6-dihydropyrimidine-5-carboxylate (19) 
A mixture of ethyl 2-(methylthio)-6-oxo-1, 6-dihydropyrimidine-5-carboxylate (361 mg, 1.685 
mmol) and 4-iodoaniline (2 eq) was heated in ethanol under reflux for 72 h.  After cooling the 
reaction mixture to room temperature, the solid residue was washed with ethanol and collected 
via vacuum filtration. After 
1





next step without further purification. Ethyl 4-hydroxy-2-((4-iodophenyl)amino)pyrimidine-5-
carboxylate (547 mg, 1.42 mmol), Na2CO3 (2 eq), and pyridin-4-ylboronic acid (1.2 eq) were 
dissolved in water/dioxane (1:2 mixture) and bubbled with N2 for 15 min. Then the Pd catalyst 
(0.1 eq) was added and the reaction was heated under 100 
o
C overnight. After the product 
formation from TLC result, the reaction mixture was cooled down to rt and diluted with 16 ml of 
water. The solution was then extracted with EtOAc (50 ml * 3). The crude product was filtered 
and air dried. Column purification first time (5% MeOH in DCM with 1% acetic acid to 20% 
MeOH in DCM with 1% acetic acid) and second time (10% MeOH in EtOAc with 1% acetic 
acid to 20% MeOH in EtOAc with 1% acetic acid) by dry loading method yield desired product 
(196 mg, 41% yield). 
1
H NMR (DMSO-D6, 300 MHz): δ 1.25 (t, J = 7.2 Hz, 3H), 4.11 (q, J = 
7.2 Hz, 2H), 7.63-7.69 (m, 4H), 8.02 (d, J = 8.7 Hz, 2H), 8.41 (s, 1H-pyrimidine), 8.53 (d, J = 
6.3 Hz, 2H), 9.08 (s, 1H-NH). 
13
C NMR (DMSO-D6, 75 MHz): δ 14.30, 21.61, 58.99, 119.67, 
120.32, 126.79, 129.51, 141.69, 146.59, 150.04, 159.47, 161.18, 165.62, 172.89. MS (ESI, QIT) 
m/z: [M + H]
+
 Calcd for C18H16N4O3 337.35, Found 337.20. 
 
Ethyl 6-oxo-2-(((tetrahydrofuran-2-yl)methyl)amino)-1,6-dihydropyrimidine-5-carboxylate 
(20) (176 mg, 47% yield). 
1
H NMR (DMSO-D6, 500 MHz): δ 1.22 (t, J = 4.2 Hz, 3H), 1.51-1.55 
(m, 1H),  1.81-1.94(m, 3H), 3.34 (br, 1H), 3.47 (br, 1H), 3.65 (q, J = 4.2 Hz, 1H), 3.77-3.79 (m, 
1H), 3.94-3.96 (m, 1H), 4.14 (q, J = 4.2 Hz, 2H), 8.37 (s, 1H-pyrimidine). 
13
C NMR (DMSO-D6, 
75 MHz): δ 14.25, 25.20, 28.20, 59.19, 67.28, 76.55, 104.14, 157.20, 158.71, 162.55, 164.14. 
MS (ESI, QIT) m/z: [M + H]
+






Ethyl 2-([1,1'-biphenyl]-4-ylamino)-6-oxo-1,6-dihydropyrimidine-5-carboxylate (21) 
(59 mg, 37% yield). 
1
H NMR (DMSO-D6, 300 MHz): δ 1.26 (t, J = 6.9 Hz, 3H), 4.19 (q, J = 7.2 
Hz, 2H), 7.33-7.36 (m, 1H), 7.43-7.48 (m, 2H), 7.65-7.72 (m, 6H), 8.51 (s, 1H-pyrimidine). MS 
(ESI, QIT) m/z: [M + H]
+
 Calcd for C19H17N3O3 336.37, Found 336.10. 
 
Ethyl 6-oxo-2-((4-(piperidin-1-yl)phenyl)amino)-1,6-dihydropyrimidine-5-carboxylate (22) 
(88mg, 55% yield). 
1
H NMR (DMSO-D6, 300 MHz): δ 1.24 (t, J = 7.2 Hz, 3H), 1.51-1.65 (m, 
6H), 3.07-3.10 (m, 4H), 4.16 (q, J = 7.2 Hz, 2H), 6.89 (d, J = 9 Hz, 2H), 7.35 (d, J = 8.7 Hz, 2H), 
8.41 (s, 1H-pyrimidine), 9.30 (br, 1H-NH). MS (ESI, QIT) m/z: [M + H]
+
 Calcd for C18H22N4O3 
343.40, Found 343.20. 
Ethyl 2-((4-morpholinophenyl)amino)-6-oxo-1,6-dihydropyrimidine-5-carboxylate (23) 
(294 mg, 59% yield). 
1
H NMR (DMSO-D6, 300 MHz): δ 1.24 (t, J = 7.2 Hz, 3H), 3.05-3.09 (m, 
4H), 3.72-3.75 (m, 4H), 4.15 (q, J = 7.2 Hz, 2H), 6.93 (d, J = 9.3 Hz, 2H), 7.40 (d, J = 9.0 Hz, 
2H), 8.41 (s, 1H-pyrimidine), 9.81 (s, 1H-NH), 11.18 (br, 1H-OH). MS (ESI, QIT) m/z: [M + 
H]
+
 Calcd for C17H20N4O4 345.37, Found 345.20. 
 
Ethyl 2-((4-chlorophenethyl)amino)-6-oxo-1,6-dihydropyrimidine-5-carboxylate (24) 
(126 mg, 25% yield). 
1
H NMR (DMSO-D6, 300 MHz): δ 1.22 (t, J = 7.2 Hz, 3H), 2.81 (t, J = 7.2 
Hz, 2H), 3.55 (br, 2H), 4.13 (q, J = 7.2 Hz, 2H), 7.27 (d, J = 8.7 Hz, 2H), 7.35 (d, J = 8.7 Hz, 
2H), 7.61 (br, 1H-NH), 8.36 (s, 1H-pyrimidine). 
13
C NMR (DMSO-D6, 75 MHz): δ 14.25, 59.20, 
104.03, 128.21, 130.64, 130.85, 137.83, 157.07, 158.90, 162.58, 164.18. MS (ESI, QIT) m/z: [M 
+ H]
+





Ethyl 2-([1,1'-biphenyl]-3-ylamino)-6-oxo-1,6-dihydropyrimidine-5-carboxylate (25) 
(246 mg, 49% yield). 
1
H NMR (DMSO-D6, 300 MHz): δ 1.25 (t, J = 6.9 Hz, 3H), 4.18 (q, J = 
7.2 Hz, 2H), 7.40-7.51 (m, 5H), 7.58-7.67 (m, 3H), 7.89 (s, 1H), 8.50 (s, 1H-pyrimidine), 10.24 
(s, 1H-NH), 11.46 (br, 1H-OH). MS (ESI, QIT) m/z: [M + H]
+
 Calcd for C19H17N3O3 336.37, 
Found 336.10. 
 
Ethyl 2-((1H-indazol-6-yl)amino)-6-oxo-1,6-dihydropyrimidine-5-carboxylate (26) 
(227 mg, 45% yield). 
1
H NMR (DMSO-D6, 300 MHz): δ 1.26 (t, J = 7.2 Hz, 3H), 4.19 (q, J = 
7.2 Hz, 2H), 7.14 (d, J = 8.4 Hz, 1H), 7.70 (d, J = 4.2 Hz, 1H), 8.00 (s, 1H), 8.11 (s, 1H), 8.50 (s, 
1H-pyrimidine), 10.52 (s, 1H-NH), 11.50 (s, 1H-OH). MS (ESI, QIT) m/z: [M + H]
+
 Calcd for 
C14H13N5O3 300.29, Found 300.10. 
 
2-(4-((5-(ethoxycarbonyl)-6-oxo-1,6-dihydropyrimidin-2-yl)amino)phenyl)acetic acid (27) 
(235 mg, 47% yield). 
1
H NMR (DMSO-D6, 300 MHz): δ 1.24 (t, J = 7.2 Hz, 3H), 3.54 (s, 2H), 
4.17 (q, J = 7.2 Hz, 2H), 7.23 (d, J = 8.4 Hz, 2H), 7.52 (d, J = 8.4 Hz, 2H), 8.45 (s, 1H-
pyrimidine), 10.21 (br, 1H-NH). MS (ESI, QIT) m/z: [M + H]
+
 Calcd for C15H15N3O5 318.30, 
Found 318.10. 
 
Ethyl 2-((1H-indazol-5-yl)amino)-6-oxo-1,6-dihydropyrimidine-5-carboxylate (28) 
(74 mg, 52% yield). 
1
H NMR (DMSO-D6, 300 MHz): δ 1.24 (t, J = 7.2 Hz, 3H), 4.17 (q, J = 7.2 





pyrimidine), 9.47 (br, 1H-NH), 11.30 (br, 1H-OH). MS (ESI, QIT) m/z: [M + H]
+
 Calcd for 
C14H13N5O3 300.29, Found 300.10. 
 
Ethyl 2-((furan-2-ylmethyl)amino)-6-oxo-1,6-dihydropyrimidine-5-carboxylate (29) 
(200 mg, 54% yield). 
1
H NMR (DMSO-D6, 300 MHz): δ 1.22 (t, J = 7.2 Hz, 3H), 4.13 (q, J = 
7.2 Hz, 2H), 4.55 (d, J = 5.4 Hz, 2H), 6.32 (d, J = 3.3 Hz, 1H), 6.40 (d, J = 4.4 Hz, 1H), 7.60 (s, 
1H), 7.73 (br, 1H-NH), 8.38 (s, 1H-pyrimidine), 11.24 (br, 1H-OH). 
13
C NMR (DMSO-D6, 75 
MHz): δ 14.24, 59.27, 104.65, 107.41, 110.50, 142.47, 151.13, 156.85, 158.71, 162.42, 164.07. 
MS (ESI, QIT) m/z: [M + H]
+
 Calcd for C12H13N3O4 264.26, Found 264.00. 
 
Ethyl 2-((4-fluorophenethyl)amino)-6-oxo-1,6-dihydropyrimidine-5-carboxylate (30) 
1
H NMR (DMSO-D6, 300 MHz): δ 1.22 (t, J = 7.2 Hz, 3H), 2.81 (t, J = 7.2 Hz, 2H), 3.55 (br, 
2H), 4.12 (q, J = 7.2 Hz, 2H), 7.09-7.14 (m, 2H), 7.25-7.30 (m, 2H), 7.53 (br, 1H-NH), 8.36 (s, 
1H-pyrimidine). 
13
C NMR (DMSO-D6, 75 MHz): δ 14.24, 59.20, 103.88, 114.82, 115.10, 
130.47, 130.58, 134.90, 134.94, 157.16, 159.25, 160.63, 162.46, 162.61, 164.23, 213.67. MS 
(ESI, QIT) m/z: [M + H]
+
 Calcd for C15H16FN3O3 306.31, Found 306.10. 
 
Ethyl 2-((4-fluorobenzyl)amino)-6-oxo-1,6-dihydropyrimidine-5-carboxylate (31) 
(64 mg, 47% yield). 
1
H NMR (DMSO-D6, 300 MHz): δ 1.21 (t, J = 7.2 Hz, 3H), 4.13 (q, J = 7.2 





(s, 1H-pyrimidine), 11.20 (br, 1H-OH).  MS (ESI, QIT) m/z: [M + H]
+
 Calcd for C14H14FN3O3 
292.28, Found 292.00. 
 
Ethyl 2-((3-fluorophenethyl)amino)-6-oxo-1,6-dihydropyrimidine-5-carboxylate (32) 
(62 mg, 43% yield). 
1
H NMR (DMSO-D6, 500 MHz): δ 1.23 (t, J = 4.2 Hz, 3H), 2.85 (t, J = 4.2 
Hz, 2H), 3.60 (br, 2H), 4.13 (q, J = 4.2 Hz, 2H), 7.03-7.12 (m, 3H), 7.33-7.37 (m, 1H), 8.38 (s, 
1H-pyrimidine), 11.07 (br, 1H-OH). MS (ESI, QIT) m/z: [M + H]
+
 Calcd for C15H16FN3O3 
306.31, Found 306.10. 
 
Ethyl 2-((2-chlorophenethyl)amino)-6-oxo-1,6-dihydropyrimidine-5-carboxylate (33) 
1
H NMR (DMSO-D6, 300 MHz): δ 1.22 (t, J = 7.2 Hz, 3H), 2.95 (t, J = 7.2 Hz, 2H), 3.59 (br, 
2H), 4.13 (q, J = 7.2 Hz, 2H), 7.25-7.60 (m, 4H), 7.60 (br, 1H-NH), 8.38 (s, 1H-pyrimidine). MS 
(ESI, QIT) m/z: [M + H]
+
 Calcd for C15H16ClN3O3 322.77, Found 322.10. 
 
Ethyl 2-((2-chlorobenzyl)amino)-6-oxo-1,6-dihydropyrimidine-5-carboxylate (34) 
(195 mg, 45% yield). 1H NMR (DMSO-D6, 300 MHz): δ 1.21 (t, J = 7.2 Hz, 3H), 4.13 (q, J = 
7.2 Hz, 2H), 4.63 (d, J = 5.1 Hz, 2H), 7.31-7.35 (m, 3H), 7.45-7.48 (m, 1H), 7.92 (br, 1H-NH), 
8.35 (s, 1H-pyrimidine). 13C NMR (DMSO-D6, 75 MHz): δ 14.23, 41.57, 59.26, 127.27, 128.67, 
128.87, 129.19, 130.10, 131.96, 135.49, 157.24, 159.01, 162.40, 164.11. MS (ESI, QIT) m/z: [M 
+ H]
+









Ethyl 2-((3-chlorobenzyl)amino)-6-oxo-1,6-dihydropyrimidine-5-carboxylate (35) 
(77 mg, 53% yield). 
1
H NMR (DMSO-D6, 300 MHz): δ 1.22 (t, J = 7.2 Hz, 3H), 4.13 (q, J = 7.2 
Hz, 2H), 4.56 (d, J = 6.0 Hz, 2H), 7.26-7.40 (m, 4H), 8.01 (br, 1H-NH), 8.36 (s, 1H-pyrimidine). 
MS (ESI, QIT) m/z: [M + H]
+
 Calcd for C14H14ClN3O3 308.74, Found 308.00. 
 
Ethyl 2-((4-chlorobenzyl)amino)-6-oxo-1,6-dihydropyrimidine-5-carboxylate (36) 
1
H NMR (DMSO-D6, 300 MHz): δ 1.21 (t, J = 7.2 Hz, 3H), 4.13 (q, J = 7.2 Hz, 2H), 4.54 (d, J = 
5.7 Hz, 2H), 7.32 (d, J = 8.1 Hz, 2H), 7.40 (d, J = 8.1 Hz, 2H), 7.78 (br, 1H-NH), 8.35 (s, 1H-
pyrimidine), 11.35 (br, 1H-OH). MS (ESI, QIT) m/z: [M + H]
+
 Calcd for C14H14ClN3O3 308.74, 
Found 308.00. 
 
Ethyl 2-((3,4-dichlorobenzyl)amino)-6-oxo-1,6-dihydropyrimidine-5-carboxylate (37) 
(80 mg, 50% yield). 
1
H NMR (DMSO-D6, 300 MHz): δ 1.21 (t, J = 7.2 Hz, 3H), 4.13 (q, J = 7.2 
Hz, 2H), 4.54 (d, J = 6.0 Hz, 2H), 7.30 (dd, J = 8.1, 1.8 Hz, 1H), 7.57-7.61 (m, 2H), 7.61 (br, 
1H-NH), 8.35 (s, 1H-pyrimidine), 11.32 (br, 1H-OH). MS (ESI, QIT) m/z: [M + H]
+
 Calcd for 
C14H13Cl2N3O3 343.18, Found 342.00. 
CHAPTER 2 
Background 
Phosphodiesterase 4(PDE4) family of enzymes and their structural information related to 
inhibitors 
cAMP is a second messenger in cells acts as a regulator for the action of neurotransmitter 
signals.
2
 It is responsible for inflammatory responses as well as cell growth, differentiation and
survival.
37
 As a cyclic nucleotide, cAMP is highly regulated by certain proteins for local
synthesis and degradation.
2
 Phosphodiesterases (PDEs), one type of these proteins, is a super
family of cyclic nucleotides which cleaves the phosphodiester bond in cAMP and causes the 
hydrolysis of cAMP, respectively. The importance of PDEs is highlighted by their sequence 
conservation among the catalytic domains of the eleven family members (PDE1-11) while they 
can still be distinguished by a unique regulatory domain.
2
 Table 6 shows the location and
function of each PDE family members.
38
PDE4 is known to be the primary cAMP-metablizing enzyme. Four genes represent 
different isoforms of PDE4 (PDE4A, B, C and D) and they all contain upstream conserved 
region 1 (UCR1) and 2 (UCR 2). UCR 2 is known to be responsible for the regulation of cAMP 
hydrolysis as well as binding affinity for Rolipram, one known PDE4 inhibitor.
2
 Besides the
UCR 1 and 2, PDE4 family can still be differentiated by their N-terminal sequences. Moreover, 
three basic isoforms can be categorized from all gene types of PDE4 (A, B, C and D) which 
include the long isoforms, short isoforms and super-short isoforms.
2





Specificities; Tissue Distribution; and Function Inhibitors 
PDE1 
(3) 
Ca2+/calmodulin-stimulated; found in heart, brain, lung, smooth muscle; PDE1A 
regulates smooth muscle contraction and plays role in sperm function.  PDE1B is 
responsible for dopaminergic signaling and immune cell activation and survival.  







cGMP-stimulated; found in adrenal gland, heart, lung, liver, platelets, endothelial 
cells; PDE2 mediates the interaction of cGMP and cAMP pathways regulating 
aldosterone secretion from the adrenal gland, cAMP and PKA phosphorylation of 
Ca2+ channels in the heart, cGMP in the neurons, long term memory, and barrier 







cAMP-selective, cGMP-inhibited; found in heart, smooth muscle, lung, liver, platelets, 
adipocytes, immunocytes; PDE3A regulates cardiac contractility, platelet aggregation, 
vascular smooth muscle contraction oocyte maturation, and regulation of renin release. 
PDE3B mediates insulin signaling, especially antilipolytic effects and regulates cell 
cycle/proliferation and mediates the inhibitory effects of leptin and other signals on 







cAMP-specific, cGMP-insensitive; found in brain, Sertolli cells, kidney, liver, heart, 
smooth muscle, lung, endothelial cells, immunocytes; PDE4 is expressed in at least 
one of its forms in most cells. The isoforms play a role in a wide array of processes, 
including brain function, momocyte and macrophage activation, neutrophilo 







Table 6 Continued 
PDE5 
(1) 
cGMP-specific; found in Lung, platelets, smooth muscle, heart, endothelial cells, 
brain; PDE5 is well-documented as a regulator of vascular smooth muscle contraction, 
especially in the penis and lung.  It is involved in NO-cGMP signaling in platelets to 








cGMP-specific; found in Photoreceptors, pineal gland, lung; PDE6 is evolved in single 








cAMP-specific, high-affinity rolipram-insensitive; found in skeletal muscle, heart, 
kidney, brain, pancreas, T lymphocytes; PDE7 is implicated to play a role in T-cell 





cAMP-selective, rolipram-insensitive; found in testes, eye, liver, skeletal muscle, 
heart, kidney, ovary, brain, T lymphocytes, thyroid; PDE8 plays a role in T cell 




cGMP-specific; found in kidney, liver, lung, brain; PDE9 has an unknown function, 




cGMP-sensitive, cAMP-selective; found in testes, brain, thyroid; PDE10A regulates 




cGMP-sensitive, dual specificity; found in skeletal muscle, prostate, pituitary gland, 
liver, heart; PDE11 is involved in sperm development and function. 
None selective 
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They all maintain the catalytic domain within the gene sequence but with major 
differences being the lack of UCR 1 or the inclusion of  a truncated UCR 2.
2
 Although no
evidence exists demonstrating the preference of PDE4 inhibitor binding towards UCR 1 or UCR 
2, a wide body of research has suggested that UCR 2 is highly responsible for the affinity of 
rolipram and related analogs compared to those isoforms only containing the catalytic domain. 
Recently, a study by Burgin et al. confirmed that the PDE4 inhibitors will interact with both 
UCR 2 and the active site of protein.
2
Previous studies on the PDE4 inhibitors 
Since cAMP regulates inflammatory responses and physiologically affects the central 
nervous system (CNS), suppression of PDE4 will yield non-metabolized cAMP, with the 
elevated level of cAMP resulting in a variety of therapeutic benefits. To be more specific, PDE4 
is a potential target mostly for the research on CNS disorders, cognitive disorders and strokes. 
Inhibition of PDE4 may also result in anti-depressant, antipsychotic and cognition enhancement 
properties.
39
 Although a large body of research has been conducted concerning the discovering
PDE4 inhibitors, most of studies are still in the early investigation stage due to the side effects 
observed for current inhibitors such as emesis and diarrhea.
40
 Examples of known PDE4
inhibitors are shown in Figure 22. The observed side effects result from the fact that competitive 
PDE4 inhibitors will not only alter cAMP concentration but will also alter the normal 




Recent research has been focused on the development of partial PDE4D inhibitors which 
are also known as allosteric modulators since they are not directly bound to the active site of 
PDE4D.  Burgin et al. have generated sufficient SAR data to indicate the pharmacophore that 
correlates to the allosteric effect of inhibitors.
2
 Generally, the desired PDE4D inhibitors contain a
planar aromatic core which provides hydrogen bond accepting capability, a linker and two other 
aromatic functional groups to help UCR 2 maintain position across the active site.  A decrease in 
the interaction of the hydrogen bond acceptor on the core and a single aromatic system in the 
core can potentially increase the possibility of partial inhibition. Additionally, the absence of the 
linker on one of the aromatic substituents will also deteremine the partial inhibitory behavior.
2
In order to evaluate the efficacy on the cognition enhancement and reduction of the 
emesis side effect, a rodent cognition test and a behavioral correlate test (ketamine/xylazine) 
were performed to show the allosteric PDE4 modulators do provide benefit on memory 
improvement as well as prevention on emetic potential.
2
 Thus, it is obvious to predict that future
discovery of PDE4 partial inhibitors will greatly increase their availability as potential drug 
candidates with minimum side effects. 
Besides the therapeutic effect on CNS, recent study suggested that PDE4 inhibitors can 
target Trypanosoma brucei, a parasite causing human African trypanosomiasis (HAT).
41
 Millions
of people are at risk of HAT and current treatments, including Melarsoprol and Eflornithine, still 
exhibit severe side effects. Research has shown that two cAMP-specific PDEs expressed in T. 
brucei, TbrPDEB1 and TbrPDEB2, are responsible for the proliferation of the parasite by both 
RNAi and small molecules.
41,42
 Furthermore, a typical human PDE4 inhibitor, Piclamilast, was
screened and was found to have inhibition against TrbPDEB1 and B2 (IC50 = 4.7 and 11.4 Μm 
respectively) (Figure 23). 
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Considering this, PDE4 inhibitors may have antibacterial activity, which provides a 
correlation between our research on the synthesis of PDE4 inhibitors and our MEP pathway 
inhibitors discovery. 
Figure 22 Examples of PDE4 inhibitors 
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Figure 23 Typical hPDE4 inhibitors showed activities against TbrPDEB1 and B2 
Revised Synthesis for PDE4D Inhibitors 
Introduction 
Three compounds have been reported as novel PDE4D partial inhibitors (D159687, 
D159404, D159153). Collaboration with Dr. Gurney at Tetra Discovery Partners LLC offered us 
a chance to investigate these compounds and provided opportunity to develop new synthetic 
pathways to obtain the desired products. 
The original six-step synthesis of D159687 is shown in Scheme 6.
43
 The aldehyde is
reduced to the corresponding alcohol with NaBH4. The 3-chlorophenyl group is then introduced 
by Suzuki coupling to afford the corresponding biaryl system. The alcohol is then converted into 
a bromide and the second aryl group is introduced using another Suzuki reaction. The urea 
functionality is introduced by reduction of the nitro group followed by urea formation. The 
overall 8% yield is observed for this method. 
To optimize the synthesis for this compound, we began to design a new synthetic 
pathway to avoid unnecessary synthetic steps and high cost of reagents. 
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Scheme 6 Six-step synthesis of D159687 
Concise two-step synthesis of D159687
44
Our revised synthesis started with dibromide compound (38) which was converted to 
desired product (41) via two sequential Suzuki coupling reactions. One possible issue in the 
process was the selectivity of coupling position. However, literature precedent and our 
experimental data all proved that the first reaction occurred at the benzylic rather than the aryl 
position. Initial attempt in synthesizing desired compound (41) suffered from low conversion and 
quantitative side products. To further optimize the reaction conditions, a variety of Pd catalysts 
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with equivalent differences were tested along with a combination of bases and solvents. (Table 
7) 
Scheme 7 Concise two-step synthesis of D159687 (41) 
As the table shows, Pd(PPh3)4 was the best catalyst for this reaction. Generally, lower 
catalyst loading increased the yield of conversion (entry 1 vs 2) with an exception (entry 15 vs 
17). This observation is due to the fact that higher catalyst loading will increase the amount of 
impurities (less than 2%) and the catalytic ligand (PPh3), which requires more excessive 
purification effort. Among the bases applied, no significant change was found for the reaction 
conversion. Moreover, reactions in anhydrous DMF exhibited the lowest conversion (resulting in 
starting material recovery) while the mixture of solvent (DME/EtOH/H2O) offered promising 
results.  
With the first Suzuki coupling reaction optimized, we applied the conditions to the 
second step with same stoichiometric conditions, altering only the reaction temperature. The 
overall outcome for these two sequential reactions offered us a gram scale of product. 
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Table 7 Optimization of conditions for the first Suzuki coupling 
Entry Catalyst Eq. Cat. Base Solvent 41 (%) 
1 Pd(PPh3)4  0.25 K3PO4  DME/EtOH/H2O (4:1:1) 54 
2 Pd(PPh3)4  0.08 K3PO4 DME/EtOH/H2O (4:1:1) 72 
3 Pd(PPh3)4  0.15 K2CO3  DME/EtOH/H2O (4:1:1) 41 
4 Pd(PPh3)4  0.15 Na2CO3 DME/EtOH/H2O (4:1:1) 50 
5 Pd(PPh3)4  0.05 Na2CO3 Dioxane/H2O (3:1) 40 
6 Pd(PPh3)4  0.25 Cs2CO3  DME/EtOH/H2O (4:1:1) 59 
7 Pd(PPh3)4 0.15 K3PO4 Dioxane/H2O (3:1) 62 
8 Pd(PPh3)4 0.15 Cs2CO3 Dioxane/H2O (3:1) 53 
9 Pd(PPh3)4 0.05 K2CO3 Dioxane/H2O (3:1) 57 
10 Pd(PPh3)4 0.05 K3PO4 DMF 1 
11 PdCl2(PPh3)2  0.05 Na2CO3 Dioxane/H2O (3:1) 44 
12 PdCl2(PPh3)2 0.25 K3PO4 DME/EtOH/H2O (4:1:1) 62 
13 PdCl2(PPh3)2 0.25 Cs2CO3 DME/EtOH/H2O (4:1:1) 56 
14 PdCl2(PPh3)2 0.15 K3PO4 Dioxane/H2O (3:1) 60 
15 PdCl2(PPh3)2 0.15 Cs2CO3 Dioxane/H2O (3:1) 64 
16 PdCl2(PPh3)2 0.05 K3PO4 DMF 6 
17 PdCl2(PPh3)2 0.05 Cs2CO3 Dioxane/H2O (3:1) 59 
18 PdCl2(PPh3)2  0.05 K2CO3 Dioxane/H2O (3:1) 61 
19 Pd(OAc)2/PPh3 (1:4) 0.25 K3PO4 DME/EtOH/H2O (4:1:1) 55 
20 Pd(OAc)2/PPh3 (1:4) 0.25 Cs2CO3 DME/EtOH/H2O (4:1:1) 52 
21 Pd(OAc)2/PPh3 (1:4) 0.15 K2CO3 DME/EtOH/H2O (4:1:1) 55 
22 Pd(OAc)2/PPh3 (1:4) 0.15 K3PO4 Dioxane/H2O (3:1) 60 
23 Pd(OAc)2/PPh3 (1:4) 0.15 Cs2CO3 Dioxane/H2O (3:1) 57 
24 Pd(OAc)2/PPh3 (1:4) 0.05 K2CO3 Dioxane/H2O (3:1) 60 
25 Pd(OAc)2/PPh3 (1:4) 0.05 K3PO4 DMF 1 
26 Pd(OAc)2/PPh3 (1:4)  0.05 Na2CO3 Dioxane/H2O (3:1) 53 
The synthesis of D159404 and D159153
44
After successfully applying a concise two-step synthesis on D159687, we aimed at 
assembling the other two PDE4D allosteric modulators, D159404 and D159153, by the same 
method. The fluorine containing intermediate 43 was obtained via the aldehyde functional group 
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installation on the commercial compound 42 followed by reduction with NaBH4 and bromination 
with NBS. As we expected, the first Suzuki coupling reaction with the boronic ester occured at 
the benzylic position of 45. The urea compound 46 underwent one more Suzuki coupling with 3-
chlorophenylboronic acid to yield D159404 (47) and with 3-nitrophenylboronic acid to yield 
D159153 (48). Modest isolated yields were recorded as 40% and 41% respectively (Scheme 8). 
Scheme 8 Synthesis of D159404 and D159153 
69 Experimental section 
General methods 
All the information regard to column purification, NMR, melting point test, analytical 
HPLC data and CHN analysis were obtained by same method. HRMS was obtained from 
University of Illinois on a Q-Tof mass spectrometer. 
1-(4-(3-bromo-4-methoxybenzyl)phenyl)urea (40):  To a mixture of bromide 38 (3.6 g, 12.86 
mmol, 1.06 eq.), boronic ester 39 (3.18 g, 12.13 mmol, 1.0 eq.), Pd(PPh3)4 (1.12 g, 0.97 mmol, 
0.08 eq.) and potassium phosphate (5.15g, 24.26 mmol, 2 eq.) in a mixture of DME (100 ml), 
water (25 ml) and ethanol (25 ml) was bubbled N2 for 25 min and then was stirred at 65
o
C for 3
hr until starting material  was consumed. After cooling to room temperature, the insoluble 
material was removed by filtration. The organic layer was evaporated and then poured into 
saturated NH4Cl (aq). The solid was collected by filtration and washed with water. Then the 
solid thus obtained was dissolved in DME (100 ml). After dried over Na2SO4, filtered, solvent 
was removed to give a residue (5.1 g), which was treated with DCM (50 ml). The desired 
product 40 was collected (2.68 g, 66% yield) as off-white solid after filtration. mp 186-195 °C; 
FT-IR cm
-1
  3459, 3335, 3300, 3202, 1655, 1570, 1525, 1493, 1253, 1051, 1017; 
1
H NMR (300
MHz, DMSO-D6) δ 3.78 (s, 2H), 3.80 (s, 3H), 5.77 (br s, 2H), 7.01 (d, J = 8.4 Hz, 1H), 7.05 (d, J 
= 8.0 Hz, 2H), 7.17 (dd, J = 8.4, 2.0 Hz, 1H), 7.29 (d, J = 8.0 Hz, 2H), 7.37 (d, J = 2.0 Hz, 1H), 
8.42 (br s, 1H); 
13
C NMR (75 MHz, DMSO-D6) δ 39.43, 56.59, 110.85, 113.09, 118.42, 129.24, 
129.40, 133.16, 134.14, 136.10, 139.08, 154.03, 156.46; Anal. HPLC (Ret time: 9.85 min, 
Area%: 98.37 %); Anal. Calcd for C15H15O2BrN2: C, 53.75; H, 4.51; N, 8.36. Found: C, 53.39; 
H, 4.66; N, 8.03.   
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1-(4-((3'-chloro-6-methoxy-[1,1'-biphenyl]-3-yl)methyl)phenyl)urea(41): To a mixture of 40 
(1.6 g, 4.77 mmol, 1.0 eq.), 3-chlorophenyl boronic acid (1.12 g, 7.16 mmol, 1.5 eq.), palladium 
catalyst (440 mg, 0.38 mmol, 0.08 eq.) and potassium phosphate (2.03 g, 9.55 mmol, 2 eq.) in a 
mixture of DME (60ml), water (15 ml) and ethanol (15 ml) was bubbled N2 for 15 min and then 
was stirred at 80
o
C for overnight until starting material 40 was consumed. After cooling to room
temperature, the insoluble material was removed by filtration. The mixture was partitioned 
between EtOAc and NH4Cl (aq.). The organic layer was separated and dried over Na2SO4.  
Removal of solvent gave a residue, which was purified by chromatography on silica gel (120 g) 
using DCM/Acetone (11:1 to 6:1). 1.18 g of product 41 (D159687) was obtained (67% isolated 
yield). mp 150-158 °C; FT-IR cm
-1
 3446, 3317, 3204, 2926, 1633, 1585, 1528, 1473, 1458,
1341, 1239, 1026; 
1
H NMR (300 MHz, DMSO-D6) δ 3.74 (s, 3H), 3.83 (s, 2H), 5.76 (br s, 2H),
7.03 (d, J = 8.1 Hz, 1H), 7.08 (d, J = 8.4 Hz, 2H), 7.15-7.20 (m, 2H),  7.28 (d, J = 8.4 Hz, 2H), 
7.48-7.36 (m, 4H), 8.40 (br s, 1H).; 
13
C NMR (75 MHz, DMSO-D6) δ 39.97, 56.08, 112.35,
118.40, 127.14, 128.41, 129.22, 129.31, 129.86, 130.31, 131.00, 133.06, 134.66, 138.94, 140.75, 
154.72, 156.47; Anal. HPLC (Ret time: 14.87 min, Area%: 98.48%); Anal. Calcd for 
C21H19O2ClN2: C, 68.76; H, 5.22; N, 7.64; Found: C, 68.50; H, 5.13; N, 7.36. 
3-bromo-2-fluoro-4-methoxybenzaldehyde (43): To a solution of 2-bromo-3-fluoroanisole 42 
(5 g, 24.39 mmol, 1 eq.) and DCM (12 ml) cooled by an ice-water bath was bubbled N2 for 15 
min.  Titanium tetrachloride (12.57 ml, 115 mmol, 4.7 eq.) and dichloromethyl methyl ether 
(3.31 ml, 36.6   mmol, 1.5 eq.) were added to the solution and stirred for 2 hrs under N2, 
warming to room temperature.  Then the solution was slowly added to ice water (625 ml) and 
extracted with DCM (2x250ml).  The organic layer was washed with saturated NaHCO3 solution 
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(187.5 ml), water (187.5 ml), and brine (187.5 ml), and dried with MgSO4.  The solvent was 
removed, and the solid titurated with hexane (37.5 ml). The solid was put under vacuum for 1 
hour.  After drying, product 43 was collected (4.7 g, 64% yield) as a tan solid. mp: 93-94°C; FT-
IR cm
-1
 3428, 3050, 2989, 2850, 2779, 2359, 1701, 1681, 1600, 1493, 1439, 1433, 1290, 1254,
1178, 1122, 1070, 846, 814, 745, 686, 611, 518; 
1
H NMR (500 MHz, CDCl3) δ 4.03 (s,3H), 6.84
(d, J = 8.5 Hz,1H), 7.88 (dd, J = 8.5, 8.0 Hz,1H), 10.24 (s, 1H); 
13
C NMR (75 MHz, CDCl3) δ
57.06, 99.60, 107.50, 118.83, 128.66, 160.67, 162.41, 185.48; Anal. Calcd for 
C8H6BrFO2•0.08H2O: C, 41.23; H, 2.60 Found: C, 40.98; H, 2.65; 
(3-bromo-2-fluoro-4-methoxyphenyl) methanol (44): A solution of 3-bromo-2-fluoro-4-
methoxybenzaldehyde 43 (4.6 g, 19.74 mmol, 1 eq.), THF (40 ml), and water (40 ml) was cooled 
to 0°C, and NaBH4 (2.24 g, 59.2 mmol, 3 eq.) was added over 8 minutes.  The solution was 
stirred for 3.5 hrs, warming to room temperature.  Then the THF was evaporated off, and water 
(90 ml) was added.  The solid was extracted with EtOAc (2x180 ml), washed with water (2x180 
ml) and brine (180 ml), and dried with sodium sulfate.  The organic solution was filtered, and the 
solvent was removed over vacuum, yielding the product 44 (3.81 g, 82% yield) as an off white 
powder.  mp: 82-83°C; FT-IR cm
-1
 3287, 2932, 2884, 1616, 1494, 1466, 1290, 1174, 1127,
1076, 1028, 941, 802, 641, 489; 
1
H NMR (300 MHz, CDCl3) δ 3.93 (s, 3H), 4.74 (s, 2H), 6.72
(dd, J = 8.4, 1.5 Hz, 1H), 7.34 (t, J = 8.4 Hz, 1H);
 13
C NMR (75 MHz, CDCl3) δ 56.64, 59.20,
99.35, 106.95, 121.25, 128.30, 156.99, 159.50; Anal. HPLC (Ret. time: 4.92 min., Area%: 
100%); Anal. Calcd for C8H8BrFO2: C, 40.88; H, 3.43. Found: C, 40.88; H, 3.29. 
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2-bromo-4-(bromomethyl)-3-fluoro-1-methoxybenzene (45): A solution of (3-bromo-2-
fluoro-4-methoxyphenyl) methanol 44 (3 g, 12.76 mmol, 1 eq.), triphenylphosphine (3.35 g, 
12.76 mmol, 1 eq.), and DCM (100 ml) under nitrogen was cooled to 0°C for 5 minutes.  NBS 
(2.272 g, 12.76 mmol, 1 eq.) was added and the reaction stirred for 2 hours at 0°C.  Then the 
solution was added to water (100 ml), extracted with DCM (2x100 ml), and dried with sodium 
sulfate.  The solution was then filtered and the solvent concentrated by vacuum to give a red oil.  
The oil was purified by chromatography on silica gel using EtOAc/hexane (0:1 to 5:95 to 10:90).  
The fractions containing product were combined, and the solvent removed under vacuum to yield 
the product 45 (3.1 g, 77%) as an off-white solid.  mp: 114-118°C; FT-IR cm
-1
 3432, 2945, 1610,
1491, 1447, 1307, 1289, 1215, 1174, 1149, 1074, 810, 615, 557, 507, 471; 
1
H NMR (300 MHz,
CDCl3) δ 3.94 (s, 3H), 4.53 (s, , 2H), 6.70 (dd, J = 8.4, 1.5 Hz, 1H), 7.32 (t, J = 8.7 Hz, 1H); 
13
C
NMR (75 MHz, CDCl3) δ 25.93, 56.71, 99.75, 107.20, 118.60, 129.95, 156.40, 159.70; Anal. 
HPLC (Ret. time: 14.94 min., Area%: 94.28%); Anal. Calcd for C8H7Br2FO: C, 32.25; H, 2.37. 
Found: C, 32.45; H, 2.19. 
1-(4-(3-bromo-2-fluoro-4-methoxybenzyl)phenyl)urea (46): 2-bromo-4-(bromomethyl)-3-
fluoro-1-methoxybenzene 45 (1.033 g, 3.47 mmol, 1 eq.), 4-(ureido)phenylboronic acid, pinacol 
ester (1 g, 3.82 mmol, 1.1 eq.), and potassium phosphate (1.472 g, 6.94 mmol, 2 eq.) were 
dissolved by ethanol (7 ml), water (7 ml), and DME (28 ml).  Nitrogen gas was bubbled through 
the solution for 25 minutes, and then tetrakis (triphenylphosphine)palladium(0) (194 mg, .168 
mmol, .05 eq.) was added.  The solution was stirred under nitrogen gas at 60°C for 3.5 hours 
until starting material was consumed.  The insoluble material was removed by filtration, and the 
organic layer removed by vacuum.  The solution was poured into saturated NH4Cl (45 ml), 
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filtered, and washed with water.  The solid was collected and dried overnight.  The solid was 
stirred in DCM (40 ml) for 30 minutes, filtered, and the off-white solid collected as the product 
46 (799.1 mg, 65%).  mp: 198-201°C; FT-IR cm
-1
 3472, 3297, 2353, 2341, 1653, 1589, 1546,
1490, 1440, 1412, 1348, 1270, 1251, 1076, 816, 780; 
1
H NMR(300 MHz, DMSO-D6) δ 3.84 (s,
5H), 5.78 (br s, 2H), 6.90 (dd, J = 8.7, 1.5 Hz 1H), 7.03 (d, J = 8.4 Hz, 2H), 7.22-7.31 (m, 3H), 
8.45 (s, 1H, NH); 
13
C MNR (75 MHz, DMSO-D6) δ 33.75, 57.09, 108.47, 118.30, 122.15, 
129.03, 130.40, 130.48, 132.64, 139.23, 155.87, 156.39, 156.44; Anal. HPLC (Ret. time: 10.28 
min,   Area%: 96.73%); Anal. Calcd for C15H14BrFN2O2•0.02H2O: C, 51.01; H, 4.00; N, 7.93. 




bromo-2-fluoro-4-methoxybenzyl)phenyl)urea 46 (760 mg, 2.152 mmol,1  eq.), 3-chlorophenyl 
boronic acid  (505 mg, 3.23 mmol, 1.5 eq.), and potassium phosphate (914 mg, 4.30 mmol, 2 eq.) 
were dissolved by ethanol (10 ml), water (10 ml), and DME (40 ml).  N2 was bubbled through 
the solution for 20 minutes, tetrakis(triphenylphosphine) palladium(0) (199 mg, .172 mmol, .08 
eq.) was added, N2 bubbled for another 5 minutes, and then the solution was stirred under N2 at 
80°C for 17 hours until the starting material was consumed.  The solution was cooled to room 
temperature, and the insoluble material was removed by filtration.  The mixture was partitioned 
between EtOAc(120 ml) and sat. NH4Cl (aq.) (120 ml).  The organic layer was separated, dried 
over Na2SO4, and the solvent removed to give oil.  The oil was purified by chromatography on 
silica gel (10.16 g) using DCM/Acetone (11:1 to 1:9), the fractions containing product were 
combined and the solvent removed by vacuum.  Ether (5.5 ml) was added to the solid, stirred for 




 3510, 3316, 2923, 2862, 1654, 1589, 1536, 1475, 1341, 1278, 1165, 1091,
1071, 742, 692; 
1
H NMR(300 MHz, DMSO-D6) δ 3.72 (s, 3H), 3.83 (s, 2H), 5.77 (br s, 2H), 6.92
(d, J = 7.8 Hz, 1H), 7.06 (d, J = 8.4 Hz, 2H), 7.23-7.31 (m, 4H), 7.36 (s, 1H), 7.40-7.48 (m, 2H), 
8.42 (br s, 1H); 
13
C NMR (75 MHz, DMSO-D6) δ 31.14, 56.52, 107.87, 116.92, 118.42, 121.09,
121.33, 127.85, 129.09, 129.72, 130.25, 130.53, 131.00, 131.10, 133.05, 134.08, 139.11, 156.30; 
Anal. HPLC (Ret. time: 16.22 min., Area%: 95.98%); Anal. Calcd for C21H18ClFN2O2: C, 65.54; 
H, 4.71; N, 7.28. Found: C, 65.33; H, 4.66; N, 7.21. 
1-(4-((2-fluoro-6-methoxy-3'-nitro-[1,1'-biphenyl]-3-yl)methyl)phenyl)urea (48): 1-(4-(3-
bromo-2-fluoro-4-methoxybenzyl)phenyl)urea 46 (500 mg, 1.416 mmol, 1 eq.), (3-
nitrophenyl)boronic acid  (354 mg, 2.124 mmol, 1.5 eq.), and potassium phosphate (601 mg, 
2.830 mmol, 2 eq.) were dissolved by ethanol (6 ml), water (6 ml), and DME (24 ml).  N2 was 
bubbled through the solution for 20 minutes, tetrakis(triphenylphosphine) palladium(0) (131 mg, 
0.113 mmol, 0.08 eq.) was added, N2 bubbled for another 5 minutes, and then the solution was 
stirred under N2 at 80°C for 17 hours until the starting material was consumed. The solution was 
cooled to room temperature, and the insoluble material was removed by filtration.  The mixture 
was partitioned between EtOAc (80 ml) and sat. NH4Cl (aq.) (80 ml).  The organic layer was 
separated, dried over Na2SO4, and the solvent removed. The solid was purified by 
chromatography on silica gel (20 g) using DCM/Acetone (9:1 to 1:9) follow by 20% MeOH in 
DCM to wash through the column, the fractions containing product were combined and the 
solvent removed by vacuum. The result solid was triturated with 5 ml ether and filtered to yield 
desired product 48 (218mg, 39% yield) as a pale yellow solid mp: 209-211°C; FT-IR cm
-1
 3458,
3302, 1647, 1592, 1523, 1351, 1272, 1093, 787, 668; 
1
H NMR (300 MHz, DMSO-D6) δ 3.74 (s,
75 
3H), 3.86 (s, 2H), 5.77 (br s, 2H), 6.97 (d, J = 8.4 Hz, 1H), 7.07 (d, J = 8.4 Hz, 2H), 7.30 (d, J = 
8.4 Hz, 3H), 7.73 (t, J = 7.8 Hz, 1H), 7.81 (dd, J = 7.5, 1.2 Hz, 1H), 8.16 (s, 1H), 8.21-8.25 (m, 
1H ), 8.43 (br s, 1H); 
13
C NMR (75 MHz, DMSO-D6) δ 33.66, 56.62, 108.02, 115.80, 118.45,
121.33, 122.90, 125.46, 129.11, 130.01, 131.60, 133.00, 133.56, 137.81, 139.14, 148.03, 156.07, 
156.45, 159.30; Anal. HPLC (Ret. time: 13.55 min., Area%: 95.43%); Anal. Calcd for 





: 396.1360, found: 396.1366.
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Synthesis of Atropisomeric PDE4D Inhibitors 
Introduction 
Atropisomerism is a term referring to stereoisomerism of a chiral molecule, and results 
from hindered rotation around a single bond (Figure 24).
45
 G. H. Christie and J. Kenner
reported the first example of an atropisomer in 1922 which related to a single enantiomer of 
6,6’-dinitro-2,2’-diphenic acid separated by diastereoselective crystallization. Multiple drug 
related molecules and natural products possess atropisomerism, which provides them 
significant biological properties including pharmacodynamics and toxicity. Several examples of 
drugs and candidates are shown in Figure 25. 
Figure 24 Comparison of traditional enantiomer with atropisomer 
77 
Figure 25 Examples of atropisomers as drug-like molecules 
The racemization of atropisomers depends upon the intramolecular dynamic processes 
that only involved bond rotation, compared to chiral compounds based on a seterogenic center 
which racemize through bond breaking and forming processes. To further understand 
atropisomers, the relationship between rotation rate and steric hindrance needs to be well 
investigated. Atropisomers can have a slow rate of interconvertion, with half-lives greater than 
1000s due to steric hindrance. This allows for the separation of such compounds under certain 
circumstances. The steric hindrance results from structural differences (Figure 26) with 
increasing rotation energy and half-time.
46
 Finally, the classification of rotation half-life
correlated to atropisomers is illustrated in Figure 27.
46
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Figure 26 The effect of functional groups on rotation energy barrier and rotation T ½










Design and synthesis of atropisomeric PDE4D partial inhibitors 
 
 After the optimized synthetic method had been developed for the PDE4 partial 
inhibitors, an additional study on their biaryl structure determined they possess atropisomerism 
because of their axial rotation ability. Despite the fact that no actual kinetic and thermodynamic 
calculations can be performed with our limited resources, a preliminary study of atropisomeric 
PDE4D partial inhibitors began with the synthesis of several analogs of the original chemical 
series, which have either halogen atoms or methoxy group installed on the biaryl system. The 
strategy behind the inhibitor design comes from a literature report suggesting energy barriers 







combination of rotational energy along with classification of atropisomers from Figure 26, 27, 
and 28 indicated that bigger substituents such as halogen or methoxy groups could potentially 
provide atropisomerism to our PDE4D partial inhibitors. Moreover, the introduction of 
atropisomerism into PDE4D partial inhibitors could result in different mechanism against 
enzymes, which will add interesting therapeutic effects on the molecules. 
 The synthesis of potential atropisomeric PDE4 partial inhibitors followed the same 
procedure as the synthesis of D159404 and D159153.
44
 The dibromo starting material was 
subjected to two consecutive Suzuki coupling with a variety of boronic esters and boronic acids 
to obtain the final products. (Scheme 9) 
 





HPLC analysis of atropisomeric PDE4D partial inhibitors 
 
 The characterization of atropisomeric compounds is generally performed on analytical 
HPLC systems outfitted with a chiral column as chiral stationary phase (CSPs) and selective 
solvent system. A variety of synthetic or natural molecules can be used as useful CSPs. In our 
case, two types of chiral columns were employed, including OD (Cellulose tris(3,5-
dimethylphenylcarbamate)) and AD (Amylose tris(3,5-dimethylphenylcarbamate)) column.. A 
typical solvent system for enantiomeric separation is a combination of n-hexane as non-polar 
mobile phase and a polar solvent such as ethanol. Having compounds prepared in methanol as 2 
mM solutions, the HPLC analysis of each potential atropismeric PDE4D partial inhibitor was 
performed on an Agilent 1100 system in our lab with a varying ratio of alkane and alcohol.  
 






Figure 30 Attempted chiral separation of 54 on chiral AD column 
 
 






Figure 32 Attempted chiral separation of 51 on chiral AD column 
 
 After a variety of solvent systems were tested for compounds 49-54, only 50 and 54 
were successfully separated by the chiral AD column, with 30% to 35% ethanol in n-hexane 
utilized as the mobile phase(Figure 29 and 30). Other compounds showed either a single or 
inseparable peak with a mixture solvent of alcohol in alkane (examples shown in Figures 31 
and 32). These results may be due to the halogen atom on the biaryl system, which does not 
provide enough steric hindrance that contributes to the rotation barrier. On the other hand, the 
methoxy group is relatively large and electron rich, which may increase the  rotational barrier 
allowing for the separation on analytical HPLC.  Additionally, because fluorine atoms should 
be considered as similar in size to protons, steric effects should not be considered as a major 
factor contributing to chiral separation. To further clarify the rationale of atropisomerism in 
PDE4D partial inhibitors, thermodynamic studies, such as ground and excited state energy 








 Six potential atropisomeric PDE4D partial inhibitors were successfully synthesized by 
the reported method and their enantiomeric properties were measured by chiral HPLC. 
Although only two compounds were separated under various conditions, they still offered a 
promising synthesis and analytical characterization method for the development of novel 
atropismeric PDE4D partial inhibitors. Additionally, compound 50 as a racemic mixture 
showed 97 nM (EC50) inhibition of cAMP via an assay performed by Dr. Mark Gurney’s group 
at Tetra Discovery Partners. This indicates these novel compounds remain as active as their 
precursors. Currently, we are working on obtaining each atropisomer and evaluating their 







(23 mg, 19% yield); 
1
H NMR (DMSO-D6, 300 MHz): δ 3.69 (s, 3H), 3.82 (s, 2H), 5.77 (s, 2H-
NH2), 7.00-7.04 (m, 2H), 7.08 (d, J = 8.4 Hz, 2H), 7.22 (dd, J = 8.4, 2.1 Hz, 1H), 7.28 (d, J = 
8.4 Hz, 2H), 7.35 (d, J = 2.4 Hz, 1H), 7.43 (dd, J = 8.4, 2.4 Hz, 1H), 7.48 (d, J = 8.7 Hz, 1H), 








H NMR (DMSO-D6, 300 MHz): δ 3.68 (d, J = 2.7 Hz, 6H), 3.81 (s, 2H), 5.77 (s, 2H-NH2), 
6.85 (d, J = 8.1 Hz, 1H), 7.06 (d, J = 8.4 Hz, 2H), 7.09-7.24 (m, 3H), 7.29 (d, J = 8.4 Hz, 2H), 




(104 mg, 62% yield); 
1
H NMR (DMSO-D6, 300 MHz): δ 3.67 (s, 6H), 4.04 (s, 2H), 7.00 (d, J = 
8.4 Hz, 1H), 7.05-7.08 (m, 2H), 7.12 (d, J = 2.7 Hz, 1H), 7.22 (dd, J = 8.4, 2.1 Hz, 1H), 7.35 
(dd, J = 8.7, 2.7 Hz, 1H), 7.53 (d, J = 8.7 Hz, 2H), 8.15 (d, J = 8.7 Hz, 2H). Anal. HPLC (Ret. 
time: 17.6 min, Area%: 100%). 
 
2,5-dichloro-2'-methoxy-5'-(4-nitrobenzyl)-1,1'-biphenyl (52) 
(103 mg, 43% yield); 
1
H NMR (DMSO-D6, 500 MHz): δ 3.71 (s, 3H), 4.08 (s, 2H), 7.07 (d, J = 
5.1 Hz, 1H), 7.12 (s, 1H), 7.31 (d, J = 5.1 Hz, 1H), 7.37 (s, 1H), 7.45 (d, J = 5.1 Hz, 1H), 7.54 









(129 mg, 60% yield); 
1
H NMR (DMSO-D6, 500 MHz): δ 3.65 (s, 3H), 4.06 (s, 2H), 6.95 (d, J = 
5.1 Hz, 1H), 7.18 (d, J = 5.1 Hz, 1H), 7.23 (d, J = 4.5 Hz, 1H), 7.35-7.50 (m, 2H), 7.53 (d, J = 
5.1 Hz, 2H), 8.17 (d, J = 5.1 Hz, 2H).  
 
5'-chloro-2-fluoro-2',6-dimethoxy-3-(4-nitrobenzyl)-1,1'-biphenyl (54) 
(120 mg, 34% yield); 
1
H NMR (DMSO-D6, 300 MHz): δ 3.69 (d, J = 5.4 Hz, 6H), 4.09 (s, 2H), 
6.91 (d, J = 5.1 Hz, 1H), 7.11 (d, J = 5.1 Hz, 1H), 7.16 (d, J = 1.5 Hz, 1H), 7.33-7.37 (m, 1H), 
7.41 (dd, J = 5.4, 1.8 Hz, 1H), 7.49 (d, J = 5.4 Hz, 2H), 8.18 (d, J = 5.4 Hz, 2H). 
 CHAPTER 3 
 
Synthesis of FOL7425 as fragment hit of MEP pathway 
 
 Our initial NMR based screening afforded three fragment hits which bind to IspD, E and 
F (Chapter 1, Figure 4, FOL7093, FOL763 and FOL7425).  Despite the low selectivity of these 
hits, an increasing activity should be observed for them compared to the fragments only targeting 
single enzyme. In order to collect the preliminary affinity of these multi-enzymes targeted 
fragments, FOL 7425 was chosen for the synthetic effort. First of all, thiourea was reacted with 
1, 3-dichloroacetone under rt to obtain the amino thiazole intermediate 55 as white precipitate. 
Then the thiazole 55 was treated with 2-mercaptobenzoxazole and K2CO3 in anhydrous DMF 
under 60 
o
C to afford compound 56 as FOL 7425 (Scheme 10). 
 
 
Scheme 10 Synthesis of FOL 7425 
 SPR assay showed the KD value as 5.9 mM which indicated a reasonable binding affinity 






Synthesis of FOL8395 as fragment hit of MEP pathway 
 
 FOL8395 was selected for the fragment hits analysis due to its potential diversity on the 
structure and a reported crystal structure (PDB: 3JVH). Future study on this chemical series will 
provide us the activity of fragment itself and build a new compound library for SAR study. The 
synthesis of FOL 8395 started with a nucleophilic addition of 2-(ethoxymethylene)malononitrile 
and hydrazine to offer pyrazole core 57. 57 was then treated with 3-nicotinaldehyde to perform a 
reductive amination. Then the cyano group was hydrolyzed by con. H2SO4 to afford compound 
59 as FOL 8395 (Scheme 11).    
 
Scheme 11 Synthesis of FOL 8395 
 
 KD value as 310 μM was observed for FOL 8395 by SPR assay. We are confident that 






Synthesis of imidazothiazole analogue 
 
 Similar to the fragment growing method of imidazole series, one imidazothiazole 
compound was synthesized based on one known fragment hit (Chapter 1, Figure 4, FOL535). 
Additionally, this imidazothiazole compound also contains part of FOL 7425 which might 
provide extra information for the binging of fragment. The pre-synthesized ester of 
imidazothiazole (prepared by Gashaw Goshu as a member of our research group) was treated 
with LiAH4 and converted to the corresponding chloride with methanesulfonyl chloride. The 
final product 62 was made by compound 61 reacted with 2-mercaptobenzoxazole (Scheme 12).  
 








Synthesis of imidazole analogs 
 
 As described in chapter 1, a hydrophobic pocket was found close to the zinc pocket. 
Derivatives create interaction with the hydrophobic pocket can potentially increase the affinity of 
the lead compounds. Based on the crystal structure of fragment FOL 995, we perform a docking 
analysis to construct a new series of imidazole compounds which have a high possibility to 
interact with the hydrophobic pocket. Synthetic effort on these compounds was performed by 
following reported methods.
48,49
 Imidazole core formation of aromatic isothiocyanate and 2,2-
dimethoxyethanamine. Compound 63 was directly reacted with aliphatic bromide to afford 65. 
Compound 64 was demethylated with BBr3 then had a neucliophilic substitution with aromatic 
bromide to give 67 (Scheme 13). SPR and other enzymatic assays are still in progress.    
 













 Two fragments (FOL7425 and FOL8395) were successfully synthesized in order to 
develop new chemical series targeting IspF enzyme. Additionally, fragment growing method was 
applied on synthesizing imidazothiazole analog and this compound can afford extra binding 
information in the future. Last but not least, a series of imidazole analogs were prepared to 
evaluate their potential interactions with the hydrophobic pocket (created by Ile59, Phe63 and 











To a solution of thiourea (0.3 g, 0.0039 mol) in acetone (15 ml) was added the solution of 
dichloroacetone (1 eq) in acetone (2.3 ml) dropwise. The reaction was allowed to stir overnight 
under rt. Filtered the white precipitate, washed it with cold acetone and dried the solid yield 
desired product 64. 
1
H NMR (300 MHz, DMSO-D6): δ 4.68 (s, 2H), 6.96 (s, 1H). 
 
4-((benzo[d]oxazol-2-ylthio)methyl)thiazol-2-amine (56) 
Compound 64 in 5 ml of anhydrous DMF was added 2-mercaptobenzoxazole (0.5 eq) and 
K2CO3 (2 eq). Then the suspension was stirred under 60 
o
C overnight. TLC indicated a fully 
conversion of starting materials. Extracted the reaction mixture with EtOAc (20 ml *2) and water 
(20 ml), dried the organic layer and removed the solvent. Column purification with a gradient of 
MeOH in DCM (100% DCM to 20% MeOH in DCM) yielded desired product 65 (0.102 g, 
34%). 
1
H NMR (300 MHz, DMSO-D6): δ 4.43 (s, 2H), 6.56 (s, 1H), 7.04 (s, 2H), 7.31-7.35 (m, 
2H), 7.64-7.67 (m, 2H); Anal. HPLC (Ret. time: 4.4 min., Area%: 99%). Anal. Calcd for 
C11H9N3OS2: C, 50.17; H, 3.44; N, 15.96; Found: C, 50.12; H, 3.44; N, 15.51. 
 
3-amino-1H-pyrazole-4-carbonitrile (57) 
2-(ethoxymethylene)malononitrile (3.0 g, 0.0246 mol) in 20ml of EtOH was added hydrazine (1 





10 ml of H2O was poured into the residue to recrystallize the product. Filtered out the remaining 
solid and washed it with cold H2O (1.2 g, 45%). 
1
H NMR (300 MHz, DMSO-D6): δ 6.02 (s, 2H), 
7.70 (s, 1H), 11.40 (br, 1H); 
13
C NMR (75 MHz, DMSO-D6): δ 73.88, 115.84, 139.35, 154.90.  
 
3-((pyridin-3-ylmethyl)amino)-1H-pyrazole-4-carbonitrile (58) 
Compound 66 (1.22 g, 0.011 mol) and 3-nicotinaldehyde (1 eq) in EtOH (15ml) was added 
piperidine (0.1 eq) dropwise. The reaction was allowed to stir under reflux overnight. After TLC 
confirmed the fully conversion of starting materials, the reaction mixture was cooled down to rt 
first and then NaBH4 (2 eq) was added into the mixture. The reaction was then stirred under rt 
for 2h. The solvent was removed and column purification was performed (100%EtOAc to 20% 
MeOH in EtOAc) to yield desired product (1.09 g, 50%). 
1
H NMR (300 MHz, CD3OD): δ 4.50 
(s, 2H), 7.39-7.43 (m, 1H), 7.86 (d, J = 7.8 Hz, 1H), 8.43 (d, J = 3.9 Hz, 1H), 8.55 (s, 1H). FT-
IR: ѵ = 2215.08 for nitrile functional group. 
 
3-((pyridin-3-ylmethyl)amino)-1H-pyrazole-4-carboxamide (59) 
Compound 67 was added con. H2SO4 (10 eq) for 20 min below 20 
o
C. Then the reaction mixture 
was allowed to warm up to rt and stir overnight. The mixture was poured into ice and neutralized 
with Na2CO3. The aqueous layer was extracted with EtOAc (20 ml*3) and the organic layers 
were combined, dried and concentrated to yield desired product (0.325 g, 30%). 
1





MHz, CD3OD): δ 4.51 (s, 2H), 7.41-7.43 (m, 1H), 7.86-7.88 (m, 1H), 8.43 (d, J = 5.0 Hz, 1H), 
8.56 (s, 1H). 
 
 
(3-methylimidazo[2,1-b]thiazol-2-yl)methanol (60)  
Ethyl 3-methylimidazo[2,1-b]thiazole-2-carboxylate (0.5 g, 0.0024 mol) in anhydrous THF (15 
ml) was added LiAH4 propotionally under 0 
o
C. The reaction mixture was then stirred for 3h 
under rt and with TLC monitoring the conversion of starting material. The reaction mixture was 
extracted with (chloroform:MeOH = 3:1, 30ml*2) and saturated NH4Cl(30 ml). The organic 
layers were combined and dried to obtain desired product (0.272 g, 67%). 
1
H NMR (300 MHz, 
DMSO-D6): δ 2.35 (s, 3H), 4.56 (d, J = 5.4 Hz, 2H), 5.55 (t, J = 5.4 Hz, 1H-OH), 7.22 (d, J = 1.5 
Hz, 1H), 7.68 (d, J = 1.2 Hz, 1H).  
 
2-(chloromethyl)-3-methylimidazo[2,1-b]thiazole (61) 
Compound 69 (0.25 g, 0.0015 mol) in dry DCM (10 ml) was added Et3N (1.2 eq) and then 
methanesulfonyl chloride (1.2 eq) under 0 
o
C. The reaction was warmed up to rt and stirred 
overnight. Extraction was performed for the reaction mixture with EtOAc (20 ml*2) and H2O 
(20 ml). The organic layers were combined, dried and concentrated to yield desired product with 
quantitative yield. 
1
H NMR (500 MHz, DMSO-D6): δ 2.48 (s, 3H), 5.10 (s, 1H), 7.34 (s, 1 H), 






Compound 70 (0.173 g, 0.00093 mol) in anhydrous DMF was added K2CO3 and 2-
mercaptobenzoxazole (1 eq). The reaction mixture was heated under 60 
o
C overnight. The 
mixture was then extracted with EtOAc (20 ml *3), H2O (20 ml*2) and brine (20 ml). The 
organic layers were combined, dried and then column purification was performed (100% DCM 
to 20% MeOH in DCM) to obtain desired product (0.08 g, 29%). 
1
H NMR (300 MHz, CDCl3): δ 
2.56 (s, 3H), 4.68 (s, 2H), 7.28-7.35 (m, 3H), 7.40 (s, 1H), 7.46-7.49 (m, 1H), 7.62-7.65 (m, 1H). 
Anal. HPLC (Ret. time: 6.8 min., Area%: > 99%). Anal. Calcd for C14H11N3OS2 • 0.2 EtOAc: C, 
55.72; H, 3.98; N, 13.17; Found: C, 55.98; H, 3.82; N, 13.12. 
 
1-phenyl-1H-imidazole-2(3H)-thione (63) 
Isothiocyanatobenzene (0.3 g, 0.0022 mol) was dissolved in toluene (5 ml) and then 2,2-
dimethoxyethanamine (1 eq) was added dropwise into the toluene solution. The mixture was 
stirred under rt for 1h. Then con. HCl was added and reaction was stirred under reflux for 3h. 
The solvent was removed and 5 ml of H2O was added. The PH of solution was adjusted to 8 by 
1M NaOH. The precipitate was filtered out and dried to yield desired product (0.261 g, 67%). 
 
1-(4-methoxyphenyl)-1H-imidazole-2(3H)-thione (64) 
1-isothiocyanato-4-methoxybenzene (1.0 g, 0.006 mol) was dissolved in toluene (5 ml) and then 





stirred under rt for 1h. Then con. HCl was added and reaction was stirred under reflux for 3h. 
The solvent was removed and 5 ml of H2O was added. The PH of solution was adjusted to 8 by 
1M NaOH. The precipitate was filtered out and dried to yield desired product (0.5 g, 61%). 
1
H 
NMR (300 MHz, CDCl3): δ 3.87 (s, 3H), 6.89 (br, 2H), 7.02 (d, J = 9 Hz, 2H), 7.50 (d, J = 9 Hz, 
2H); 
13
C NMR (75 MHz, CDCl3): 55.57, 114.37, 114.88, 119.91, 126.09, 127.33, 130.31. 
 
Ethyl 2-((1-phenyl-1H-imidazol-2-yl)thio)acetate (65) 
Compound 72 (0.256 g, 0.0015 mol) was dissolved in EtOH (5 ml) and ethyl 2-bromoacetate (1 
eq), Et3N (1 eq) were added. The reaction mixture was heated under reflux for 3h and then 
extracted with EtOAc (20 ml*2) and H2O (20 ml). The organic layers were combined, dried and 
concentrated to yield desired product (0.292 g, 77%). 
1
H NMR (300 MHz, CDCl3): δ 1.25 (t, J = 
7.2 Hz, 3H), 3.98 (s, 2H), 4.17 (q, J = 7.2 Hz, 2H), 7.15 (d, J = 1.2 Hz, 1H), 7.20 (d, J = 1.5 Hz, 
1H), 7.40-7.51 (m, 5H).  
 
1-(4-hydroxyphenyl)-1H-imidazole-2(3H)-thione (66) 
Compound 73 (0.81 g, 0.0039 mol) in anhydrous DCM (20 ml) was cooled down to -70 
o
C and 
then BBr3 solution (12 ml) was added dropwise into the solution. The reaction was then warmed 
up to rt and stirred for 2h. Poured 20 ml of H2O into the reaction mixture and filtered out the 
precipitate as desired product (0.463 g, 62%). 
1
H NMR (300 MHz, CD3OD): δ 6.89 (d, J = 8.7 







4-(2-((4-chlorobenzyl)thio)-1H-imidazol-1-yl)phenol (67)  
Compound 75 (0.1 g, 0.00052 mol) was dissolved in EtOH (3 ml) and 1-(bromomethyl)-4-
chlorobenzene (1 eq), Et3N (1 eq) were added into the solution. The reaction mixture was then 
heated under reflux for 3h. The mixture was extracted with EtOAc (20 ml*2) and H2O (20 ml). 
The organic layers were combined, dried and concentrated to yield desired product (0.123 g, 
75%). 
1
H NMR (300 MHz, CD3OD): δ 4.03 (s, 2H), 6.79 (d, J = 9.0 Hz, 2H), 6.88 (d, J = 9.0 Hz, 
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C NMR SPECTRA of FOL7425, FOL8395, IMIDAZOTHIAZOLE 
ANALOG and IMIDAZOLE ANALOGS  
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